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ABSTRACT
Dougherty, Kevin S. M.S., Department of Neuroscience, Cell Biology and
Physiology, Wright State University, 2007. The Development and Molecular
Expression in Mammalian Cells of an HA-Tagged Plasmid Encoding for the
Target of Rapamycin (mTOR).

The protein kinase Mammalian Target of Rapamycin (mTOR) is a master
controller of cell growth and proliferation due to its ability to integrate growth
signals and regulate translation through 4E-BP1 and p70-S6K. We developed
four phCMV2-HA-tagged plasmids to overexpress TOR in mammalian cells: Wild
Type, D2357E (Kinase Dead), R2109A (PA Binding Deficient) and, S2035T
(Rapamycin Resistant) each verified by restriction enzyme digestion and direct
sequencing. Plasmid DNA was overexpressed in COS-7 cells and the 289 kDa
protein detected in Western blots developed with anti-HA and anti-mTOR
antibodies. Kinase activity of the overexpressed protein was detected by in vitro
phosphorylation of 4E-BP1 and S6K. QRT-PCR detected a 200 fold increase in
mTOR gene expression over mock transfected cells, but found no change in
PLD2 gene expression. Immunoflourescence microscopy indicated that mTOR
is perinuclear, concentrated in endosomal formations. This study provides the
molecular biology tools for continuing investigation into the crosstalk between
mTOR, S6K, PLD1 and PLD2.
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I. LITERATURE REVIEW
Discovery of mTOR
During a 1970’s expedition to Easter Island, off the coast of Chile, South
America, researchers discovered a strong antifungal metabolite produced by the soil
bacteria Streptomyces hygroscopicus1. The newly discovered macrolytic lactone was
named rapamycin after the island where it was found, which is called Rapa Nui in the
local language2. Further study revealed immunosuppressive properties and the ability
to inhibit mammalian cell growth while the macrolydes mechanism of action
remained a mystery. The addition of rapamycin to cell cultures results in G1 arrest in
a variety of cell types3. In 1980’s the National Cancer Institute screening program
demonstrated the anti-tumor activity of rapamycin 4. These findings caused a flurry of
research aimed at identifying the biochemical actions of rapamycin5. By 1991 the
extraordinarily specific target of rampamycin was identified though mutations
TORC1 and TORC2, which confer resistance to rapamycin, and aptly named Target
of rapamycin (TOR)6.
Advances in biochemistry lead to the cloning of the “mammalian target of
rapamycin” (mTOR), also known in the literature as “FK506-binding protein”
(FKBP12), “rapamycin-associated protein” (FRAP), “rapamycin and FKBP12 target”
(RAFT1), “rapamycin target” (RAPT1), or “Sirolimus effector protein” (SEP) 7. For
the purposes of this thesis, we will use the first nomenclature. Every eukaryotic
genome examined to date contains a mTOR gene8. The TOR protein is highly
conserved from yeast to man, sharing about a 95% homology at the amino acid level,
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suggesting that it plays a vital role in cellular function9. Genetically mTOR maps to
the human chromosome 1p36.27.

Cellular Importance of mTOR
mTOR is known to sense mitogenic stimuli, extra cellular nutrient levels10 and
ATP11.

It also regulates cell functions including actin reorganization of the

cytoskeleton,12 cell growth and proliferation,13 cell survival,14 transcription,
translation initiation,15 mRNA turnover, protein stability,12 and repression of
autophagocytosis (Figure 1). Dysregulation of the mTOR signaling pathway16 is
common in cancerous tumors including lung, bladder, renal, ovary, breast, prostate,
gastric, pancreatic, and head and neck carcinomas17. Dysregulation of the mTOR
pathway has also been observed in lymphomas, melanoma, glioma and several other
brain diseases18. Unusually high mTORC1 activity is suspected as an underlying
cause of these cancers19.
mTOR has been shown to be essential in development of mouse embryos,
causing severe birth defects to mouse knockout mutants20. Studies in Drosophila
melanogaster and Caenorhabditis elegans have identified TOR as essential in
embryonic development as well21. Disruptions of the mTOR gene in mice result in
embryonic lethality with severe telencephalon malformation, termed the “flat-top”
phenotype. Embryonic tissues requiring a rapid increase in cell proliferation, such as
the telencephalon, limb buds and ventral body walls were malformed in the mTOR
mutant genotype.

This finding seems to implicate mTOR in sensing mitogenic

signals and upregulating cell proliferation. Hentges’ et al. showed no measurable
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FIGURE 1:
mTOR plays a vital role in signaling cell growth, proliferation and survival. The
signaling network consists of two major branches, TORC1 and TORC2.
TORC1 responds to growth factors including insulin and insulin-like growth
factors and controls several pathways that determine the mass of the cell.
The TORC1 acts largely through the control of the PI3K pathway,
phosphorylating downstream targets, S6K and 4E-BP1 to control protein
synthesis.

The TORC2 pathway is less well understood but has been

implicated in cell survival and proliferation as well as control of the actin
cytoskeleton, effectively regulating the shape of the cell. Main pathways are in
black, with feedback loops depicted in red. Arrows indicate activation of the
downstream molecule, while inhibition of the downstream molecule is
indicated with a stopped line. Pathways which are yet unclear are indicated
by dashed lines and question marks. Direct phosphorlyation is indicated with
the letter ‘p’ in a red circle. Figure adapted from Guertin, 2005.
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difference in cell size in the mTOR mutant mice compared to a wild type mouse20.
This finding seemingly does not agree with previous reports that Drosophilia TOR
mutants had a smaller average cell size than their wild type counterpart22.
Characteristics of the “flat-top” phenotype include a failure to upregulate
neuronal formation in the forebrain and inability to maintain gene expression in the
prechordal region of the forebrain neuroectoderm20. “Flat-top” mouse embryos die at
12.5 days post coitus. The same lab showed no survival differences in TOR mutated
embryo’s versus wild type TOR embryo’s treated with rapamycin21. After injecting
rapamycin into wild type pregnant mice and observing effects similar to those in
mTOR mutant mice they were able to assert that the malformed embryos were due to
a disrupted mTOR pathway. This experiment reinforced the tetrogenic effects of
rapamycin and demands its further study as an anticancer drug16.

mTOR Structure
mTOR is a 289 kDa protein Serine/Threonine kinase which belongs to a
family of phosphatidylinositol kinase-related kinases (PIKK)23. After TOR mutants
TOR1-1 and TOR2-1were identified24 a group of high molecular weight kinases
including TOR, were identified that resembled the phosphoinositide 3-kinase
family(PI3K). This new family which shared sequence homology and were found in
all eukaryotic cells was given the name phosphoinositide 3-kinase related kinases
(PIKK’s)25. There are several subfamilies of PIKK’s including TOR subfamily,
Atazia telangiectasia mutant,24 the ATM gene product and the DNA-dependent
protein kinase. PIKK’s are usually involved in functions critical to cell survival and
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often regulate cellular responses to DNA damage, repair and recombination. PIKK’s
are also known to regulate cell cycle progression and cell checkpoints26.
mTOR contains several conserved DNA sequences (Figure 2)27. It contains a
C-terminal kinase domain similar to protein and lipid kinases that is critical for the
function of this family of kinases28. mTOR also contains a unique domain at the
extreme C-terminus end that are not seen in PI3 and PI4 Kinases20.
The first 1200 amino acids of the mTOR sequence make up approximately 20
tandemly repeated motifs composed of Huntington, elongation factor 3, the A subunit
of protein phosphatase 2A (PP2A), and TOR 1p (HEAT domains).

The motif

consists of patterns of approximately 40 amino acids in 3 repeating sequences, each
containing the pattern of the hydrophobic; proline, aspartic acid, and arganine
residues7. The HEAT domains modulate protein to protein interactions through an
extended superhelical structure, but their exact function is yet unknown12.
Carboxy-terminal to the HEAT domains is the short segment of amino acids,
termed the FAT domain, unique to PI3K’s. Found between amino acids 1382-1982
the FAT domain is always paired with the FATC domain at the extreme carboxy
terminus of mTOR29.

The FATC domain gains its name from its components

including: rapamycin-associated protein (FRAP), ataxia telangiectasia mutated
(ATM), and transformation/transcription domain-associated protein (TRAAP), and its
position at the carboxy-terminus. While the FATC domain is unique to mTOR,
researchers have suggested that the presence of the FAT and FATC domains serve to
regulate kinase activity in mTOR7. Conservation of the FAT and FATC domains is
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FIGURE 2:
A schematic representation of the structure of the mTOR protein. The
first 1200 amino acids are patterns of approximately 40 amino acids in 3
repeating sequences.
interactions.

This domain modulates protein to protein

The FAT domain is a 600 amino acid sequence that

modulate the function of the kinase domain. Conservation of this domain
is critical to mTOR kinase activity. The FRB domain is the location of the
binding site for which PA and FKBP12 compete. The kinase domain is
critical for cell cycle progression as mutations in this site lead to G1 cell
cycle arrest.

This domain is also responsible for phosphorylation of

downstream components of the mTOR pathway. The FATC domain is
always paired with the FAT domain and is equally critical for kinase
activity.
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critical as even the smallest change in amino acid sequence can cause mTOR to lose
its kinase activity.
Carboxy-terminal to the FAT domain is the FKBP-12-rapamycin binding
(FRB) domain, which binds the FKBP-12-rapamycin dimer. Mapped from 2025 to
301430, mutations in the FRB domain can confer rapamycin resistance to mTOR and
have been exploited to allow a deeper understanding of the pathways with which
mTOR is involved. The FRB domain also plays a role in the upstream regulation of
mTOR.

Studies have shown that FKBP1231, which is known to bind the FRB

domain, was competitive with phosphatidic acid (PA) for that site. The FRB domain
contains a serine residue Ser2035 which is critically involved with the binding of the
FRB region and the FKBP12-rapamycin complex. Mutations at this residue with any
other amino acid containing a larger side chain than serine prevent the proper tertiary
complex formation32.
The mTOR kinase domain is carboxy-terminal to the FRB domain. The
protein kinase domain resembles the catalytic domain of PI3K’s and holds an affinity
for serine and threonine residues33. The kinase domain in mTOR is essential for cell
cycle progression that mTOR mediates. Mutations in the kinase domain lead to G1
cell cycle arrest 34.

This domain is also required for the phosphorylation of

downstream components including S6 Kinase and 4E-BP1 and is interchangeable
within the PI3K family35. mTOR does not have any known lipid kinase activity36,
although it does autophosphorylate37.
mTOR is also thought to play a role in nuclear shuttling, which may have
some regulatory effect on the downstream molecules, S6K and 4E-BP1. mTOR is
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considered cytoplasmic, generally localized to intracellular membranes38. There is no
known reason for mTOR’s localization to intracellular membranes, however. Chen’s
lab has also shown data which suggests that the continuous movement of mTOR from
the cytoplasm to nucleus has implications in S6 Kinase activation and
phosphorylation39. Although mTOR has no conventional nuclear export or import
signal, it is possible that it contains a novel transport sequence enabling it to move in
and out of the nucleus40. The lack of a clear nuclear localization sequence is not
uncommon in the ATM-related kinase family though, and may explain the apparent
lack of sequence. Another proposed hypothesis is that mTOR translocates only after
associating with an unknown transport vehicle containing a standard nuclear shuttling
protein39. Ongoing research in different labs is aimed at confirming or disproving
mTOR’s need for such a shuttling vehicle.
Chen’s lab performed a number of experiements to determine the effect of
mTOR shuttling. Using leptomycin B (LMB), a specific inhibitor of the nuclear
export receptor Crm1, the lab showed that the mTOR pathway was significantly
inhibited in the presence of LMB39. LMB treatment led to an inhibition of 4E-BP1
phosphorylation and S6K activity.

In other experiments with S6K2, Chen’s lab

concluded that: “It is thus likely that a balanced distribution of mTOR between the
cytoplasm and nucleus, or an optimal shuttling rate of mTOR, may be essential for
the maximal activation of downstream signaling41.”

TORC1 and TORC2
mTOR exists as two different multiprotein complexes within the cell42 (Figure
3). TOR complex 1 (TORC1) is composed of mLST8/GβL (mLST8 is also called G
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Proteins associated with TORC1 and TORC2.
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protein β-subunit-like protein) and Raptor (regulatory-associated protein of mTOR)
and shows rapamycin sensitivity. To date, the function of mLST8/GβL is unknown,
although it may serve as an activator molecule43. TORC1 controls many of the
known pathways of the mTOR complex including phosphorylation of S6K1 and 4EBP1. TORC1 is also responsible for transcription and translation initiation, thereby
controlling the growth and proliferation of the cell44.

TORC2 is composed of

MLST8/GBL and RICTOR-PROTOR45 (rapamycin-insensitive companion of mTOR
and protein observed with RICTOR) complex, but shows no rapamycin sensitivity42.
TORC2 is responsible for actin reorganization within the cell as well as
phosphorylation of AKT at S47344.
TORC1 and TORC2 respond differently to rapamycin. TORC1, complexed
with GBL and raptor proteins, show sensitivity to rapamycin. Rapamycin and its
receptor protein FKBP12 directly bind to and inhibit mTOR at the FRB domain.
Although the mechanism is poorly understood46, recent studies suggest that the
rapamycin/FKBP12 complex competes with the activator molecule PA for mTOR
binding sites. By interfering with the mTOR pathway, the effected cell is not able to
proceed into the G1 phase of the cell cycle thereby unable to synthesize protein.

Upstream Regulators of mTOR
There are several known upstream regulators of mTOR. It is known that
nutrient depravation or starvation conditions inhibit pathways that require mTOR47,
while insulin, insulin like receptors, and nutrients such as amino acids or glucose
upregulate mTOR48. Protein synthesis is one of the most energy consuming tasks the
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cell undertakes; therefore, it is easy to see why the cell strictly regulates these
processes. Individual cells must constantly assess mitogenic and nutritional signals
around them and determine if enough raw materials exist for growth or
proliferation49. DNA and protein synthesis leading to an increase in individual cell
size defines growth. An increase in the number of cells in a population is termed
proliferation50.
Eukaryotic cells have complex, and not yet fully understood mechanisms that
regulate protein synthesis and breakdown. When cells sense a lack of raw materials
including amino acids, oxygen, or growth factors cellular processes begin which
prevent growth or proliferation51. In times of need, the cell may even catabolize
translational machinery for the raw materials in order to maintain homeostasis. In a
severe crisis, such as a lack of nutrients, cells initiate apoptotic pathways that
eventually lead to the cells demise. In times of abundance however, TOR functions
to upregulate translation, cell growth, and actin reorganization.

PI3K Pathway
Currently the best understood mTOR activation pathway is through PI3Kinase (Figure 1). In this pathway, mTOR is activated through various extracellular
growth factors including Insulin and Insulin-like growth factor-1 (IGF-1)52. Insulin
and IGF-1 signal through integrins and chemokines through G-protein coupled
receptors to the Insulin Receptor Substrate (IRS) in the plasma membrane of the cell.
IRS then recruits PI3-Kinase to the cell membrane 49. The newly recruited PI3-Kinase
binds to phosphatidylinositol-4,5-phosphate (PIP2) in the cell membrane and converts
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it to Phosphatidylinositol-3,4,5-phosphate (PIP3), a cell survival signal53.

PIP3

recruits PDK1 and Protein Kinase B (Akt) to the membrane, binding the pleckstrin
homology (PH) domain of Akt. This causes PIP3 to dimerize, exposing its active
catalytic site54. PIP3 activates PDK1, which in turn phosphorylates and activates
AKT49.

AKT
AKT is of particular interest because of its important role in apoptosis
inhibition. Phosphorylated AKT promotes cell proliferation through mTOR while
inhibiting phosphorylation and activation of proteins such as the pro-apoptotic Bad
protein55. Tumor suppressor genes phosphatase and tensin homolog (PTEN) and
inositol polyphosphate-5-phosphatase D (SHIP) inhibit the phosphorylation of AKT
by PI3K in a regulatory mechanism that prevents overgrowth56. However in some
cancers, PTEN is found to be mutated and the lipid phosphatase that inhibits the PI3kinase activity is not functional57. This dysregulated pathway then can not prevent
the overexpression of cancerous cells, allowing cell proliferation regardless of
nutrient status. Cancers with apoptotic resistant cells are commonly linked to PTEN
mutations7. AKT may also directly phosphorylate mTOR or act as an inhibitor of
Tuberous Sclerosis Proteins 1 and 2 (TSC1 and TSC2) by phosphorylation of TSC258.

Tuberous Sclerosis Complex (TSC1 and TSC2)
Distal to AKT in the activation pathway of mTOR is the Tuberous Sclerosis
Complex. The TSC1/TSC2 complex is composed of the proteins hamartin (TSC1)
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and tuberin (TSC2) which bind to mTOR in vivo, and also acts as a GTPaseactivating protein of Rheb. TSC2 is an inhibitor of mTOR through Rheb, but when
TSC2 is phosphorylated by AKT, its inhibitory effects are downregulated7. The
precise mechanism through which the TSC1/TSC2 complex is inhibited is yet
unclear, but some reports suggest it is through the dissociation of the TSC complex59.
When the PI3K pathway looses the inhibitory effects of the TSC1/TSC2 complex, the
cell shows an mTOR dependent increase in p70S6K activity.

This increase in

p70S6K activity provides the cell with a small level of resistance to amino acid
depravation59. In nutrient poor environments, the TSC1/TSC2 complex inhibits the
phosphorylation of p70S6K.
Recently studies have shown that the TSC1/TSC2 complex may also have a
nutrient sensing path independent of the AKT pathway. In cell lines where the
TSC1/TSC2 was mutated out, the expected p70S6K dephosphorylation response to
nutrient depravation is not seen. This seems to suggest that the TSC1/TSC2 complex
somehow signals nutrient levels to the cell, and that disturbing the TSC1/TSC2
complex serves to destroy that sensing pathway10.

Rheb
Rheb is the last step in the PI3K pathway before mTOR. Rheb is a small Gprotein activator of mTOR. TSC2 is a GAP (GTPase-activating protein) for Rheb.
Non phosphorlyated TSC2 acts as a Rheb inhibitor by converting the active GTPbound form of Rheb to the inactive GDP version. However, when the TSC1/TSC2

13

complex is inactivated through AKT phosphorlyation, Rheb transforms into its active
GTP-bound protein and upregulates mTOR60.
Recently, Rheb has been shown to bind directly to the kinase domain on
mTOR, in a GTP-dependant manner61. Rheb’s high GTP levels allow it to bind
mTORC1, causing a conformational change in mTORC162. This conformational
change leads to the activation and phosphorylation of the two best known
downstream targets: 4E-BP1 and p70 S6K. Gain of function Rheb mutants have been
shown to be more active in promoting phosphorylation of 4E-BP1 and p70 S6K63.
Most researchers would agree that Rheb binds mTOR but Rheb’s mechanism
of interaction to activate mTOR remains unclear. This is largely because it is difficult
to detect direct interactions between Rheb and mTOR64. It is also unclear what role
GTP plays in the pathway. Some labs have even suggested that Rheb and mTOR
actually act in parallel pathways as opposed to the linear pathway presented here9.

Phosphatidic Acid (PA)
Phosphatidic acid (PA) is a lipid second messenger used in several
intracellular pathways and regulates an ever expanding list of signaling proteins. PA
has been implicated as a mediator of mitogenic upregulation by hormones and growth
factors65. The precise mechanism by which PA acts on mTOR is yet unknown, but
some labs have reported that PA is a requirement for mTOR to phosphorylate S6K65.
After serum stimulation, a rapid rise in PA levels is observed, and correlates with
activation of mTOR signaling in human embryonic kidney (HEK) cells.
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PA is most commonly a product of the enzymatic activity of phospholipase D
(PLD), addressed later in this discussion66. PA is composed of a glycerol backbone
with carbons 1 and 2 forming ester-links to fatty acids. The terminal carbon group
links to a phosphate group, forming the negatively charged polar head group. There
are at least three enzymes that are capable of PA generation: lysophosphatidic acid
acyltransferase, and diacylglycerol kinase (DGK)67 and PLD.
Diacylglycerol kinases (DGK) are a conserved family of lipid kinases that
phosphorylate diacylglycerol (DAG) to produce PA. DAG is a second messenger
whose cellular levels have been shown to increase transiently with extracellular
fluxuations of growth factors and hormones. DAG is also activator of protein kinase
C (PKC), and other GTPase-activating proteins including those in the Ras family of
GTPases68.
PA production by PLD can be suppressed by a reaction involving primary
alcohols. In the transphosphatidylation reaction, an inert phosphatidyl-alcohol is
produced instead of PA when reacting PLD2 with primary, but not tertiary alcohols.
In this reaction, the primary alcohol replaces the water molecule and acts as the
nucleophillic acceptor. The alcohol competes with the water to be the hydroxyl donor
forming a phosphatidylalcohol. This is a commonly used reaction as an in vitro PLD
activity assay69. The control experiment to rule out any effect of the alcohol not
related to PLD is performed by using a tertiary alcohol instead of a primary alcohol
that is not a substitute for PLD.
Several labs have shown that PA production through PLD is an essential event
for mitogenic activation of mTOR . Cellular concentrations of PA are normally less
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than 5% than that of phosphatidylcholine (PC), but during mitogenic activation the
amount of PA within a cell increases, most likely due to PLD activation70. Using
0.3% 1-butanol, serum stimulated PA production can be effectively stopped65. Using
the same transphosphatidylation reaction, 1-butanol was able to almost completely
block the serum stimulated phosphorylation of S6K1 and 4E-BP1.

The

phosphorylation of serum stimulated activation of extracellular signal-regulated
kinases (ERK1 and ERK2) was not affected by the presence of the 1-butanol. This
experiment established the specificity of 1-butanol on PA production and implicates
the involvement of PA in the phosphorylation of S6K and 4E-BP171. From these
findings, it can be asserted that PLD production of PA plays an essential role in the
mTOR signaling pathway. The suppression of PA generated through PLD has been
reported by a number of labs to inhibit the mTOR pathway in several cell phenotypes.
The lab led by Dr. Jie Chen has also shown evidence that PA binds to mTOR
at the FKBP12-rapamycin-binding (FRB) domain.

Small unilamellar vesicles

(SUV’s) containing purified FRB fragment bound to PA in very low concentrations65.
This binding was specific for PA as other phospholipids were unable bind the FRB
with such specificity. The FRB region is where the rapamycin-FKBP12 molecule
binds mTOR as well. It is hypothesized that the competition between the rapamycinFKBP12 complex and PA for the FRB site may be one of the regulating factors in
mTOR activation71. Researchers previously suggested that the rapamycin-FKBP12
molecule induces a conformational change in the structure of mTOR72. However new
data suggests the effects of rapamycin are realized through the competitive interaction
between mTOR’s FRB and PLD generated PA. Yet a third hypothesis suggests that
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the pH locally around mTOR is reduced by PA generated PLD. mTOR is then
pronated in a way that promotes its kinase activity, or allows for interaction with yet
unknown promoter substrates53.
Attempts at corroborating mTOR phosphorylation studies using exogenously
provided PA have been inconclusive. Some labs have reported exogenously supplied
PA was able to incorporate easily into cellular membranes and participate in cellular
functions73. Others however, reported that signaling was disrupted in siRNA PLD2
knockdown cells, even with the presence of exogenously provided PA74. Recently
there have been some questions about the validity of studies involving exogenously
provided PA. It is difficult for PA to cross cellular membranes and reach appropriate
sites to engage mTOR, and exogenously provided PA may activate mTOR as a result
of another, yet unknown pathway53.

The Role of mTOR in Hypoxia
During low oxygen conditions, mammalian cells immediately down-regulate
energy consuming processes75. Translation is one of the first processes to be effected
as the cell seeks to stave off the impending energy crisis. Hypoxia also upregulates
HIF-1, a transcription factor which activates genes required for the cell’s adaptation
to the new environment 13. Because it is yet unknown what pathways regulate HIF-1
in response to hypoxia, some have suggested mTOR as a potential mediator of the
extracellular condtions76. However, other studies have shown that mTOR and S6K1
can respond to amino acid availability independently of the TSC1/2 pathway77.
Hypoxia mimics rapamycin causing the dephosphorylation of mTOR and its
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downstream effecter proteins, 4E-BP1 and S6-Kinase.

These effects have been

observed independently of the growth factors previously discussed in this review.
These findings suggest yet another unresolved pathway that mTOR may use to effect
the cell78.

Downstream Molecules of mTOR/Raptor (TORC1)
Ribosomal S6 Kinase
The best characterized function of mTOR is translation regulation72. The S6K
isoform, S6K-1 is a major ribosomal protein in mammalian cells, and responsible to
phosphorylate the S6 ribosomal protein79. The ribosomal S6 subunit of the 40S
ribosome selectively increases translation of some of the mRNA’s containing the 5’Terminal Oligopyramidine Tract (5’-TOP)39. mRNA’s with a 5’-TOP often serve to
encode ribosomal proteins and other transcription regulation proteins thereby
upregulating transcription80. S6K is independent of mTOR81 however, even low
concentrations of rapamycin are thought to inhibit the phosphorylation activity of
S6K24. While the actions of S6K are not well understood48, S6K1 likely plays an
important role in the regulation of cell cycle progression, cell growth and cell
proliferation82.
Structurally, the S6K protein is divided into four regions: the acidic NH2
terminus, the catalytic domain, a linker region and a basic COOH- terminus
containing an autoinhibitory pseudosubstrate domain83. Current data suggests that
S6K remains in an inactive state with its acidic NH2-terminus interacting with the
basic COOH region, stabilizing the protein.
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This conformation allows the

pseudosubstrate region to autoinhibit the catalytic domain of S6K.

After

phosphorylation of several C-terminal sites, the S6K undergoes a conformational
change and releases the pseudosubstrate, allowing the phosphorylation of T389 in the
catalytic domain82.
The mTOR and PI3K pathways can phosphorylate at least eight sites on S6K.
These phosphorylation events are known to require several mediator molecules
including PDK1, AKT, PKC, and the small G proteins Cdc42 and Rac182. It is likely
that there are other yet unknown mediator molecules. Only the phosphorylation of
T229 on S6K’s activation loop of the kinase domain has been described84. The
remaining phosphorylation sites, while identified, remain less well understood. Two
phosphorylation sites serine 371 and threonine 389 are known to be required for S6K
activity85. Experiements show that mTOR can phosphorylate T389 directly in vitro
while the kinase responsible for S371 is not yet known33. However, incubation with
rapamycin causes dephosphorylation of threonine 229 and serine 404 suggesting
mTOR’s involvement with those residues as well.
Additionally, evidence now shows that mTOR phosphorylation is mediated by
p70 S6 Kinase52. This feedback mechanism phosphorylates SER-2448 on mTOR,
and does not appear to be controlled by the AKT pathway. This may be a negative
feedback mechanism86.
It has been shown that inhibition of mTOR signaling by rapamycin treatment
leads to a dramatic decrease in rRNA gene transcription and pre-rRNA processing87.
This includes the dephosphorylation of T389, the principle rapamycin-sensitive site,
leading to the kinase inactivation of S6K51. This evidence suggests that mTOR
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signaling is a vital link in sensing nutrient availability and regulating ribosome
biogenesis on the basis of that information88. Inhibition of mTOR signaling has been
shown to inhibit translation as well, but in a less dramatic fashion than its inhibition
of transcription89.

In mice, disruption of S6K1 leads to reduced animal size,

suggesting a role for S6K1 in the control of cell size and growth. Amino acid
depletion also causes S6K dephosphorylation, through the mTOR pathway, in a
manner which is reversible by the replenishing of the addition of amino acids.
Ribosome synthesis is a hallmark indicator of cellular growth regulation. As
nutrients become more readily available, cells upregulate ribosome synthesis,
allowing for a rapid size increases and proliferation. As was previously discussed,
this process is energy intensive and must be strictly regulated for survival purposes.
HeLa cells, for example, produce about 7,500 ribosomes per minute, requiring the
transcription of 150-200 rRNA genes and involving the synthesis of approximately
300,000 ribosomal proteins47. This tightly regulated process would be impossible
except for the systematic interactions between nutrient sensing pathways and with
coordinated support from assembly factors, ribonucleases, small nucleolar
ribonucleoprotein particles and RNA helicases. This has been previously explained
by Fingar et al. in their article on mTOR.
“If the rate of cell growth is unable to keep up with the rapid rate of
cell division, then cell proliferation cannot be sustained, since cells
would progressively loose mass and size with each division cycle,
resulting in inevitable cell death. Therefore, proliferating cells exhibit
tight coordination between cell growth and cell cycle progression. In

20

addition, such coordination ensures that individual cells, and indeed
organs and whole organisms, maintain a characteristic size.” 83
Recently a second S6 Kinase was discovered, S6K241. S6K2 shows an 80%
homology to S6K1 and is also phosphorylated in a rapamycin dependant manner.
Unlike its cytosolic counterpart S6K1, however, S6K2 is nuclear, due to its Cterminal nuclear localization signal (NLS)90. Much less is known about S6K2 than
S6K1, but current models suggest redundant functions. S6K1 is thought to play a
more crucial role in growth control than S6K250.
The membrane-to-nucleus PI3K-mTOR pathway is beginning to reveal itself
as more than just a linear pathway. Mounting evidence points to the hypothesis that
the PI3K pathway operates under the nutrient sensing influence of mTOR only to a
certain degree. Amino acid and energy sufficiency are mediated by mTOR primarily,
while growth factors, hormones, and mitogens sufficiency are conveyed through the
PI3K pathway and then to mTOR.

4E-BP1
Cells treated with mTOR inhibitor rapamcyin arrest at the G1/S boundary and
mimic the physiological state of starved G0 cells25. mTOR kinases, in the presence of
adequate amino acids, upregulate the signaling pathways by activating eukaryotic
translation initiation factor 4 E (eIF-4E) protein synthesis, effectively inducting G1
progression91. The 12 kDa polypeptide 4E-BP1 is a strong repressor or eIF-4E,
important for translation. By regulating energy use within the cell, mTOR serves as
an effective gatekeeper.
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In its inactive state when nutrients or growth factors are scarce, 4E-BP1 is
hypophosphorylated and binds tightly to the 7-methylguanosine cap-binding protein
eIF4E to inhibit eIF4E function91. Upon the return of adequate nutrients and growth
factors, 4E-BP1 is phosphorylated and dissociates from eIF4E. eIF-4E is then able to
specifically recognize and bind the 5’cap on a nuclear transcribed mRNA. Almost all
nuclear transcribed mRNA contain a 5’ cap structure; m7GpppN, (where ‘m’ stands
for any methyl group and ‘N’ any nucleotide)92. eIF-4E is also available to bind the
scaffolding protein eIF4G and assemble the translation initiation complex. While the
translation initiation complex forms, eIF4G also interacts with eIF3, recruiting the
40S subunit to the 5’ end of the mRNA93. Because the binding sites for 4E-BP1 and
eIF4G overlap on eIF4E, their binding is competitive and mutually exclusive,
ensuring 4E-BP1’s ability to regulate eIF4E’s activity.
Phosphorlyation and activation of 4E-BP1 is sensitive to mTOR inhibitors
including rapamycin and other PI3K pathway inhibitors. Studies in vitro show that
immunoprecipitated mTOR phosphorlyates threonine 37 and threonine 46 on 4EBP1, suggesting mTOR as the active kinase in vivo33. These two sites are considered
priming sites, as phosphorylation of serine 65 and threonine 70 must follow for eIF4E to be released by 4E-BP1. The kinase for the phosphorylation of these sites is yet
unknown, but mTOR may also act as the kinase there. In all, 4E-BP1 has seven
known phosphorylation sites: Thr 37, Thr 46, Ser 65, Thr 70, Ser 83, Ser 101 and Ser
11292.

As is expected then, inhibition of mTOR by rapamycin results in the

hypophosphorylation of 4E-BP1.
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TOR “Signaling Motif”
Both S6-Kinase and 4E-BP1 contain a TOR Signaling (TOS) motif, which
may be recognized by the Raptor-mTOR complex.

A functional TOS motif is

required for mTOR to phosphorylate S6K1 and 4E-BP1 in vivo, as destroying this
domain mimics rapamycin treatment of mTOR94. Studies show that an inactive TOS
motif on 4E-BP1 is unable to bind mTOR and results in abnormally small cell growth
and small cell size95. The mTOR/raptor/4E-BP1 complex will not properly form in
the absence of a functional TOS motif. These experiments lead to the hypothesis that
raptor interacts with mTOR to form a substrate presentation scaffold, and without the
properly functioning regions, is ineffective at phosphorlyating downstream
substrates43.
The homology demonstrated in the TOS regions of S6K and 4E-BP1 is not
unique, however, and is demonstrated in many other proteins72.

This lack of

specificitiy makes it difficult to identify sequences for which mTOR has a remarkable
affinity. Also, phosphorylation sites are not conserved between the two molecules.
This has lead some to propose that mTOR associated proteins may actually determine
the substrate preference, leaving mTOR’s kinase domain with no preference in
substrate33. It is difficult then to prove with any certainty that S6K and 4E-BP1 are
direct substrates of the mTOR-raptor complex.
Due to the nature of the many substrates that are apparently involved with the
mTOR signaling path, there is mounting concern about the disruption of those
proteins in vitro83. Recent studies show that mTOR and it associated proteins are
easily disrupted with nonionic detergents. This may be one explanation for the
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apparent disparity in kinase activity experiments and provide insight into why
mTOR’s in vitro kinase activity correlates poorly with the activation and
phosphorylation of expected downstream targets in vivo83.
Evidence continues to mount pointing to a possibility that there are one or
more intermediate kinases that regulate the downstream molecules of mTOR. This
kinase or may be regulated by or associate with mTOR in interactions that are yet
unknown. This possibility should continue to drive research forward to elucidate the
precise mechanism by which mTOR is regulated.

Clinical Applications
As was previously discussed, mTOR and its pathways are commonly
overexpressed or mutated in cancer. Clinical studies on several prototype mTOR
inhibitors, all rapamycin analogs, (CCI-779 [Wyeth], RAD001 [Novartis] and
AP23573 [Ariad Pharmaceuticals] are currently taking place16. However, these drugs
have only shown promise is a few cancers. The overall response to rapamycin
treatments has been variable, with success often linked to certain cell types.
Several unexpected results of rapamycin-analog treatments have presented
themselves. The first is the existence of a strong negative feedback loop from S6K to
AKT49. This loop inhibits AKT when mTOR is activated which can promote cell
survival and chemoresistance48.

The very cancerous cells which the drug is

attempting to eradicate may, in fact enter a survival mode, allowing them to survive
and proliferate under stressful conditions such as nutrient or space deprivation. The
second unexpected result of treatment is that prolonged rapamycin treatment has been
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shown to lead to the inhibition of the mTORC2-RICTOR complex. This complex
was previously thought to be insensitive to rapamycin. The cause for this finding is
yet unknown, but it is speculated to be mediated through the AKT pathway.
The development of safe, effective pharmaceutical agents to counteract the
dysregulation of the AKT/mTOR pathway in cancer should be a key focus of mTOR
research right now. However, this goal will not be able to be reached until the
complexity of the mTOR protein complex and the crosstalk between other signaling
molecules are more fully realized. Defining the connection between the mTOR
associated proteins and its kinase activity is an important challenge for the future.
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II. HYPOTHESIS AND SPECIFIC AIMS

We hypothesize that mTOR can be overexpressed in a mammalian
system and a complete study of this expression (protein activity and
subcellular localization) can be pursued, taking advantage of an HA tag.

AIM 1:
Prepare an HA-tagged mTOR expression plasmid.

AIM 2:
Generate three HA-tagged mTOR mutated plasmids by site directed mutagenesis.
Including:
PA binding deficient R2109A
Kinase Dead D2357E
Rapamycin Resistant S2035T

AIM 3:
Detect protein expression of plasmids by Western blotting; probe with anti-HA and
anti-mTOR.
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AIM 4:
Determine enzyme activity of overexpression plasmids (mock, HA-mTOR, Kinase
Dead) using KLISA, Mass Spectrometry, or gamma ATP to detect phosphorylation of
mTOR substrates.
Substrates 4E-BP1, S6K
Use Rapamycin, a known mTOR inhibitor as a negative control.

AIM 5:
Investigate the effects of mTOR transfection on gene expression and subcellular
localization.
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III. MATERIALS AND METHODS
Materials
COS-7 cells were purchased from American Type Culture Collection (ATCC)
(Rockville, MD). mTOR, PLD1, PLD2 and, S6K Taqman gene expression assays
purchased from Applied Biosystems (Foster City, CA). Protease Inhibitor cocktail
set III, microcystin-LR and, K-LISA mTOR activity kit purchased from Calbiochem (
San Diego, CA). Dulbecco’s Modification of Eagle’s Medium (DMEM) purchased
from Cellgro (Herndon, VA). HA-Tag (6E2) Mouse mAb purchased from Cell
Signaling Technology (Danvers, MA). TrichromRanger prestained molecular weight
marker mix, 4-20% Precise Protein gels and, Scintiverse II scintillation cocktail
obtained from Fischer Scientific (Chicago, IL). Enhanced chemiluminescence (ECL)
Western blotting detection reagents purchased from GE Healthcare (Piscataway, NJ).
phCMV2-HA vector (4.26 kb) purchased from Gene Therapy Systems (San Diego,
CA). Various primers purchased from Integrated DNA Technologies Inc. (Coralville,
IA).

Lipofectamine, plus reagent, Opti-MEM reduced serum medium, Quant-iT

Ribogreen RNA assay kit, dNTP’s, SuperScriptII reverse transcriptase, random
primers, single strand reverse transcriptase buffer, RNase out, Deoxyribonuclease I
and, DTT purchased from Invitrogen (Carlsbad, CA). UltraClean Plasmid Prep Kit
purchased from MOBIO Laboratories, Inc. (Carlsbad, CA). Quick Ligation Kit, Taq
DNA Polymerase and ThermoPol Buffer, Restriction Enzymes and their buffers,
Lambda DNA-HindIII Digest and, Antarctic Phosphatase, purchased from New
England BioLabs Inc. (Ipswich, MA). Homo sapiens FK506 binding protein 12rapamycin associated protein 1 (FRAP1) Human cDNA clone (also known as mTOR)
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purchased from OriGene Technologies, Inc. (Rockville, MD). [32P] γ−ATP (500 µci)
purchased from Perkin Elmer (Waltham, MA).

RNeasy minikit, Quiaquick gel

purification kit and, QIAprep Spin Miniprep kit were purchased from Qiagen Inc.
(Valencia, CA). 4E-BP1 (FL), HA-probe (Y11), α-myc-TRITC IgG antibody and, aHA-FITC IgG antibody purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA).

Monoclonal Anti-HA, Influenza Hemagglutinin Protein (HA-Tag) and,

Influenza Hemagglutinin (HA) Peptide purchased from Sigma (St. Louis, MO).
QuikChange XL Site-Directed Mutagenesis Kit, 96 well PCR plates, DH5α gold
cells, and Brilliant II QPCR master mix purchased from Strategene (La Jolla, CA.).
P70 S6 Kinase (T412E), active purchased from Upstate Biotechnology (Lake Placid,
NY). ExoSAP-IT, DNA Ladder (1 KB), Agarose, molecular biology grade ultra pure
water and, 10X TAE buffer purchased from USB Corporation (Cleveland, OH).
Vectashield mounting media purchased from Vector Labs (Burlingame, CA). Ion
exchange chromatography cellulose phosphate paper purchased from Whatman
(Hillsboro, OR).
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Methods
DH5α Transformation
This experiment was begun with a Homo sapiens FK506 binding protein 12rapamycin associated protein 1 (FRAP1) Human cDNA clone (known for the
purposes of this thesis as mTOR) purchased from OriGene Technologies, Inc. This
DNA clone was the starting point of the thesis and the building block from which the
four other plasmid constructs would come.
The filter containing the purchased, dried DNA clone was placed in a sterile
eppendorf with 10 µl ultrapure water to achieve a final concentration of 100 ng/µl.
DH5α cells (100 µl) were thawed on ice to which 50 ng of eluted plasmid was added.
The cell-plasmid mixture was occasionally swirled and incubated on ice for 30
minutes. The mixture was then heat shocked for 45 seconds at 42° C, and chilled on
ice for 2 minutes. Room temperature SOC media (900 ml) was added and the cells
incubated at 37°C for 1 hour in a shaker at 230 RPM. After 1 hour 150 µl of the
SOC-cell mixture was spread onto LB/Agar/Ampicillin solid media plates.
Individual colonies of the DH5α transformed with pCMV6-XL4-mTOR were
selected and inoculated in 5 ml LB/Ampicillin. These were incubated at 37°C for 8
hours before mixing 850 µl of the bacterial culture and 150 µl glycerol to make
glycerol stocks. Glycerol stocks were stored at -70°C.

DNA Preparation – Maxiprep
For maxiprep DNA preparation we used the UltraClean Plasmid Prep Kit
purchased from MOBIO Laboratories, Inc. The manufacturer’s instructions were
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followed to obtain large quantities of DNA from cell cultures. One ml bacterial
culture was added to 400 ml LB/Ampicillin and incubated in the shaker, overnight at
37°C.

The next day the culture was prepared per the protocol provided with

MOBIO’s Plasmid Prep Kit. The cells were pelleted at 4500xg and resuspended in 5
ml Solution 1. The pellet was lysed by alkaline treatment by adding 10 ml Solution 2,
and inverting 5 times. Thirty ml Solution 3 neutralized the mixture, after which it
was inverted again 5 times. The cell mixture was centrifuged for 20 minutes at
4500xg, which allows for the separation of the DNA from the proteins. The pellet
and floating protein and lipid mixture at top of the liquid were discarded. The filter
column was centrifuged dry at 3600xg for 5 minutes. Then 2 ml of 65C ultrapure
water was added to the column and centrifuged into a clean centrifuge column.

Restriction Enzyme Digestion
Five hundred ng of plasmid was incubated with 1 µl of the appropriate buffer,
a minimum of 20 units of enzyme as required, and 1 µl of BSA as required. All
restriction enzymes were obtained from New England BioLabs, and the
manufacturer’s instructions for digestion reactions were followed.

One unit of

enzyme is defined as the amount of enzyme required to digest 1 µg of λ DNA in 1
hour at 37°C in a total reaction volume of 50 µl. The total volume of the reaction was
then taken to 10 µl and incubated at 37°C for a minimum of 2 hours.

After

incubation, 2 ml gel loading buffer was added to each digestion and the mixture was
loaded into a 1% agarose gel. The gel was run at 100V for approximately 40 minutes,
until the marker bands were clearly separated. Images of the gels were captured
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under ultraviolet light with Kodak’s Gel Logic 200 image system using Capture GL
Molecular Imaging Software version 4.0.1.

Mutagenesis
Mutagenesis was performed as outlined in Stragagene’s QuikChange XL SiteDirected Mutagenesis Kit. Fifty ng of purified plasmid was added to 5 µl 10X
mutagenic buffer. Sense and antisense mutagenic primers (0.65 µl) were then added.
Primers were designed at www.idtdna.com and purchased from that same company
(Tables 1, 2). The primers were stored at a stock concentration of 200 ng/µl in TE,
pH 7.5. One µl dNTP’s, three µl QuikSolution, and ultrapure water to 49 µl were
added.

Next 1 µl Pfu Turbo polymerase was added, the mixture mixed and

centrifuged. The mutagenesis reaction was placed in the PCR machine and cycled.
After the PCR reaction was complete, 1 µl Dpn I was added and allowed to react for
1 hour at 37°C. This mutagenic, Dpn I-treated PCR reaction was then used to
transform XL10 cells.

XL-10 Cell Transformation
To transform the mutagenesis reaction, 45 ul XL10 competent cells were
added to 2 µl β-Mercaptoethanol and incubated on ice for 10 minutes. Next, 2 µl of
the Dpn I-treated mutagenesis reaction was added, and incubated for 30 minutes on
ice. The mixture was then heat shocked at 42°C for 30 seconds after which it was
placed on ice for 2 minutes. NZY+ media (450 µl) was preheated to 43°C and added
to the reaction. This mixture was incubated for 37°C for one hour in the shaker at
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Primer

Mutagenic Primer Sequence

mTOR
(Mfe/Hind)
Sense
mTOR
(Mfe/Hind)
Antisense

5’ – GAGGCCTTGGCCGAAGCCGCGCCAATTGCAGG
GCAAGCTTCTTGGAACCGGACCTGCCGCCGC -3’
5” – GGCGGCGGCAGGTCCGGTTCCAAGAAGCTTGC
CCTGCAATTGGCGCGGCTTCGGCCAAGGCCTC– 3’

TABLE 1:
Mutagenic primers were designed to introduce two point mutations into
pCMV6-XL4-mTOR to introduce two new restriction sites, HindIII and MfeI to
the plasmid. These sites allowed for removal of the mTOR insert and ligation
into the phCMV2-HA vector. The sequence underlined and in red above is
the HindIII point mutation.

The sequence underlined and in blue represents

the MfeI mutation. After mutation, digestion with HindIII and the NotI, a site
which was already present in the mTOR sequence, released the mTOR insert
from the pCMV6 backbone and allowed for purification of the sequence. The
sticky ends created by digestion with HindIII and NotI of mTOR correspond to
the same sticky ends created in the phCMV2-HA plasmid with the same
digestion.

These complementary sticky ends provided ideal ligation

conditions.
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Primer

Mutagenic Primer Sequence

mTOR D2357E
Sense

5’ - GATCCTGCACATTGAATTCGGGGACTGCTTTG - 3’

mTOR D2357E
Anti-sense
mTOR R2109A
Sense

5’ – CAAAGCAGTCCCCGAATTCAATGTGCAGGATC – 3’

mTOR R2109A
Anti-sense
mTOR S2035T
Sense
mTOR S2035T
Anti-sense

5’ – CTCTATTATCATGTGGTCGCGAGAATCTCAAAGCAGC – 3’
5’ – GCTGCTTTGAGATTCTCGCGAACACATGATAATAGAG – 3’
5’ – GCCTGGAAGAGGCAACACGTTTGTACTTTG– 3’
5’ – CAAAGTACAAACGTGTTGCCTCTTCCAGGC– 3’

TABLE 2:
Mutagenic primers were designed to introduce two point mutations into
phCMV2-HAmTOR-WT to introduce new restriction sites to the plasmid.
These sites allowed for the detection of the mutation by restriction enzyme
digestion after cells are transformed. The sequences underlined and in red
represent the mutation sites.

The D2357E plasmid contains an EcoRI

mutation, the R2109A plasmid contains an NruI mutation and the S2035T
contains an AflIII mutation.
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230 RPM. After incubation, 200 µl of the transformation reaction was plated on
LB/Agar/Ampicillin solid media plates and incubated overnight at 37°C.

DNA Preperation - Miniprep
For DNA miniprep we used Qiagen’s QIAprep Spin Miniprep Kit and
followed the manufacturer’s detailed instructions.

Briefly, the 3 ml cultures of

transformed XL-10 or DH5α cells were pelleted at 4000x g for 10 minutes and the
supernatant removed. The pellet was resuspended in 250 µl buffer P1 and transferred
to labeled 1.5 ml eppendorf tubes per the instructions provided in Qiagen’s Plasmid
miniprep kit. Buffer P2 (250 µl) was added, and the tube inverted 6 times. Buffer N
(350 µl) was added, and the contents of the tube centrifuged at 18,000x g for 10
minutes. The supernatant was passed through the Miniprep columns by centerfuging
at 18,000x g for 2 minutes, flow through being discarded. Column filters were
washed with 750 µl buffer PE and centrifuged to dry. Filters were eluted with 50 µl
buffer EB into clean eppendorf tubes.

DH5α Transformation with pCMV6-mTOR
DH5α cells were transformed with pCMV6-mTOR plasmid. The procedure
follows a similar protocol to the one described for the transformation of pCMV6XL4-mTOR plasmid. Fifty ng of plasmid was used to transform 100 µl competent
DH5α cells. Individual colonies were selected from the solid agar/ampicillin plates
and 5 ml cultures of LB/ampicillin were inoculated and grown for 5 hours at 37°C.
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The two most confluent cultures after 5 hours were used to prepare the 200 ml
LB/ampicillin broth for maxiprep.

Purification of mTOR Insert
Five µg of pCMV6-mTOR and 50 Units of HindIII were combined with the
appropriate buffers and incubated at 37°C for 6 hours. After inactivation of HindIII
for 20 minutes at 65°C, 50 Units of NotI was added with the appropriate buffer. This
mixture was incubated overnight at 37°C.

Gel purification of the mTOR insert

proceeded per Qiagen’s QIAquick Gel Extraction protocol.

Digestion and Dephosphorylation of phCMV2-HA
Five µg of the phCMV2-HA vector was combined with 50 Units of HindIII
and the appropriate buffers. This mixture was incubated for 6 hours at 37°C. After
heat inactivation of HindIII for 20 minutes at 65°C, 50 Units of NotI were added with
appropriate buffers and the mixture was incubated overnight at 37°C. The phCMV2HA vector, with HindIII and NotI sticky ends was dephosphorylated with Antarctic
Phosphatase.

Ligation of Hind IIIphCMV2-HANot I and Hind IIImTORNot I
Fifty ng of dephosphorylated
with a 3-fold molar excess of purified

Hind III

phCMV2-HANot

Hind III

I

vector was combined

mTORNot I insert. Ten µl of 2X ligation

buffer was added, followed by 1 µl of T4 DNA Ligase. The mixture was centrifuged
and incubated at room temperature for 5 minutes. The ligation reaction was chilled
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on ice and then used to transform DH5α cells. Transformation of DH5α cells with
the phCMV2-HAmTOR-WT plasmid proceeded as outlined previously with
adjustments made for the ligation mixture. Five µl ligation mixture was added to 100
µl XL-10 cells and mixed by gently pipetting up and down. The transformation
reactions were plated on LB/agar/Kanamycin solid media plates. These plates were
incubated overnight at 37°C.

Generation of the phCMV2-HAmTOR-WT Plasmid
Primers were ordered from www.IDTDNA.com to allow sequencing around
the ligation site of the phCMV2-HAmTOR-WT plasmid (Table 3). PCR primers
were stored in stock concentrations of 100 pmol/µl. Each PCR reaction contained 15
µl PCR buffer, 1 µl dNTP’s, 1 µl MgSO4, 1 µl primer set, 42 µl water, 0.25 µl Taq
Polymerase DNA and, approximately 10 pg plasmid.

The sense/antisense “535

primer set” were used in one reaction and a second reaction contained the
sense/antisense “716 primer set.” Ten µl of PCR sample was added to 4 µl of
ExoSAPit and mixed. The reaction was incubated at 37°C for 15 minutes followed
by 80°C for 15 minutes.

Cell Transfection and Lysate Preparation
Plasmid transfection to mammalian COS-7 cells was carried out under
standard transfection conditions, using Invitrogen’s Lipofectamine and Plus reagents
as vehicles for the plasmids to enter the COS-7 cells. Six well plates were used, wells
with cell confluency from 50% to 80%. Each well received 600 µl of cold Opti-mem,
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Primer

Primer Sequence

HAmTOR-535
sense

5’ – AATGGGCGTGGATAGCGGTTTGAC-3’

HAmTOR-535
antisense

5’ – CTAGATGTGGTGGCAGCGGTGGTG – 3’

HAmTOR-716
sense

5’ – GCAAATGGGCGGTAGGCGTGTA – 3’

HAmTOR-716
antisense

5’ – ACTGGGTCATTGGAGGGGAGGAGGTTC – 3’

TABLE 3:
PCR Primers were designed against phCMV2-HAmTOR-WT to enable
sequencing of the ligation site near the HA tag. The 535 primer set gave
fragment 535 bp in length, and the 716 primer set gave a 716 bp fragment
when run on a 2% agarose gel.
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5 µl of Lipofectamine and 5 µl of Plus reagent along with the proper amount of
plasmid. After a 48 hour incubation at 37°C, with controlled humidity and 5% CO2,
the cells were harvested. Cell lysates were taken from COS-7 cells transfected with
each of the 4 plasmids.
Lysates were obtained using a lysis buffer modified from Kim et al.10; 50 mM
Tris HCL, 100 mM NaCl, 10% Glycerol, 1% Tween 20, 1 mM EDTA, 25 mM NaF,
50 mM B-Glycerolphosphate, 1:200 Sigma Phosphatase Inhibitor Cocktail I, 1:200
Calbiochem Protease Inhibitor Cocktail Set III. This buffer was named KLISA Lysis
Buffer (KLB). Cells were scraped from their wells, and rinsed with lysis buffer
before being sonicated for 10 seconds. After sonication, the fragments were pelleted
via centrifugation for 2 minutes at 14,000 RPM.

Protein concentration was

determined using the BioRad Protein Assay Kit, with the plates read by an Amersham
BioTrack II plate reader.

Western Blotting
SDS-PAGE gels were run using Pierce 4-20% Precise Protein gels and
TrichromeRanger Prestained Molecular Marker.

Gels were run at 70 Volts for

approximately 90 minutes. The proteins embedded in the SDS-PAGE gels were
transferred to PVDF membranes during a 70 mA, 1.5 hour transfer. The PVDF
containing the proteins were dried overnight and Western Blotting was performed the
next day. Western Blotting was performed with 1:750 anti-mTOR and 1:5000 antirabbit IgG and Horseradish Peroxdase. Additional experiments used 1:1000 anti-HA
Primary antibody and 1:5000 anti-mouse IgG. Amersham’s ECL Reagents were used
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to wash the PVDF’s and then in a dark room, mounted to X-Ray film in a cassette.
Film was developed 24 to 48 hours later.

Kinase Assay
A recipe for a 2X mTOR Kinase Assay buffer was found published by Kim et.
al. 39. Kim’s Kinase Buffer is composed of; 50 mM Hepes-KOH (pH 7.4), 100 mM
KCL, 40% glycerol, 20 mM MgCl2, 8 mM MnCl2, 2 mM DTT, 100 µm ATP.
Using 19 µl of 2X Kim Kinase Assay Buffer, 20 µl COS-7 cell lysate and 1 µl
of either p70 S6 Kinase (T412E), or 4E-BP1, the cell lysates were tested for kinase
activity. The mass spectrometer used SAX2 Protein Chips by Ciphergen. 1 µl SPA
supernatanent was loaded on top of each of the samples and allowed to dry. The
chips were then run in the mass spectrometer and the data analyzed for peaks
indicating phosphorylated proteins.
A second, different, kinase assay used COS-7 cell lysates that were
immunoprecipitated with anti-mTOR antibodies to concentrate the mTOR.

This

assay consisted of 140 µl cell lysate, 100 µl LB2, 8 µl HA-agarose beads were
combined and incubated at 4°C in a rotator for 2 hours. After 2 hours the beads were
washed with cold LiCL and NaCl and resuspended in Lysis Buffer. Kim’s 2X Kinase
buffer was modified to create a 4X buffer, while the glycerol concentration was
reduced to 20%.
For the [32P] γ−ATP kinase assay, 12.5 ml Kim’s 4X buffer, 1 µci
[32P] γ−ATP, 23.8 µl H20, 12.5 µl immunoprecipitated HA-agarose bead suspension,
and either 1 µl S6K or 1 µl 4E-BP1 were incubated for 25 minutes at 37°C. After
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incubation, the reactions were boiled for 7 minutes, with strong vortexing every 2
minutes. Fifty µl of the supernatant was loaded into the Pierce 4-20% Precise Protein
gel. Gel was run at 70 V for approximately 100 minutes, or until the wavefront was
run off the gel. After the proteins were transferred to a PVDF membrane, the PVDF
was loaded into a film cassette with X-ray film and stored overnight at -70°C. X-Ray
films were exposed for a period of 24 hours up to two weeks.

Real Time PCR
COS-7 cells were transfected with pc-DNA-myc-PLD2, and phCMV2HAmTOR-WT plasmids under conditions described previously.

Cell lysate was

obtained by scraping the wells and rinsing the lysate with TBS. Using the Qiagen
RNeasy Minikit, RNA was extracted from the cell lysate. The obtained RNA was
subject to DNase treatment, following the protocol provided with Invitrogen’s
DNAase I kit. Next, an aliquot of the RNA was removed for quantification purposes.
A 6.3 µl aliquot of RNA was quantified against an RNA standard using Molecular
Probes Ribogreen RNA Quantitation Kit. Then an equal quantity of RNA from each
sample of DNA treated RNA was then reverse transcribed to cDNA. The cDNA was
then stored at -70°C.
The RT-PCR is set up such that each transfection condition is probed with
each of the probes designed against mTOR, S6K, PLD1 and PLD2. A Master Mix of
25 µl Stratagene Brilliant III Supermix, 1 µl of the respective probe/primer set, 3 µl
Glucuronidase housekeeping gene probe/primer set, and 16 µl H20 was prepared for
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the RT-PCR reaction. The cDNA from each condition was added and the RT-PCR
reaction run per the protocol provided with the supermix.

Immunoflourescence Microscopy
COS-7 transfected cells were fixed on glass coverslips by adding 1 ml 4%
paraformaldehyde to each cover slip. After a 10 minute incubation period at room
temperature the paraformaldehyde was aspirated and cells permeabilized with 1 ml
0.5% Triton X-100 in PBS.

Permeabilized cells were incubated on at room

temperature for another 10 minutes. Cells were then blocked with 1 ml 10% fetal
bovine serum in 0.1% Triton X-100 in PBS.

Cells were incubated at room

temperature for 4 hours. Cells were probed by adding 1 ml of 1:1000 anti-HA FITC
antibody conjugate in blocking buffer solution. The 6-well plate was then covered
and stored in the dark at 4°C overnight. Any excess antibody was aspirated from the
coverslips, and then the coverslips were washed with 1 ml PBS. Probing with 1:1000
TRITC Phalloidin dye followed. After aspiration of anti-TRITC, 1 ml 1:2000 DAPI
dye in PBS was used to stain nuclei. Coverslips were incubated at room temperature
for 5 minutes in the dark. DAPI was aspirated and coverslips washed 3X with PBS.
Coverslips were rinsed with ddH20 and allowed to air dry. Coverslips were mounted,
cell side down onto a glass microscope slide with a drop of Vectashield mounting
media between the coverslip and slide.
An Olympus Fluoview Laser scanning confocal microscope with a 60X
objective was used to view the slides. Images were captured and analyzed using
MetaView v.6.0 software from Universal Imaging Co.
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IV. RESULTS
Aim 1: Prepare an mTOR Expression Plasmid.
This lab has previously carried out studies using siRNA’s and Real Time
PCR.

In her thesis, Farnaz Tabatabaian, M.S., developed a cell model of

differentiated HL-60 cells and transfected them with siRNA’s using an Amaxa
electroporator 96. She was able to quantitate gene expression levels of PLD1, PLD2,
mTOR and S6K. Using siRNA technology, Tabatabaian sought to determine the
impact of PLD gene silencing and its impact on mTOR and S6K levels. These
studies provided insight into protein expression and gene regulation within several
different cell lines however, they lacked investigation into mTOR and its effect on
cell lines. This was largely because the lab had no way to over-express the mTOR
protein kinase. The development of such a molecular tool was one of the aims of the
present thesis and provides a method to specifically investigate the role mTOR plays
in the cell (Figure 4).

pCMV6-XL4-mTOR
An mTOR expression plasmid construct was readily obtainable from
commercial sources. For this thesis we purchased a Homo sapiens FK506 binding
protein 12-rapamycin associated protein 1 (FRAP1) Human cDNA clone (also known
as mTOR) from OriGene Technologies, Inc. (Rockville, MD). This plasmid was 13,
394 base pairs and contained an mTOR open reading frame of 8.7 kilobases linked to
a 4.7 kilobase pCMV6-XL4 backbone (Figure 5). This plasmid was named pCMV6XL4-mTOR. However, the backbone of the plasmid did not contain any sequences

43

HA-Tagged mTOR Plasmid Generation Process

R2109A

R2109A

D2357E

S2035T

FIGURE 4:
Scheme outlining steps taken to develop an HA-tagged mTOR construct for
this thesis.
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CMV primer
T7 promoter
NotI (973)

XhoI (10737)

EcoRI (980)

M13 reverse primer

KpnI (1007)

SV40 ORI

SacI (1196)

SmaI (9730)
SacII (9702)

NheI (1336)

pCMV6-XL4-mTOR

BamHI (1844)

13394 bp

NotI (9696)

XhoI (2534)

XbaI (9687)

BamHI (3747)

XbaI (9601)

SmaI (3793)

BamHI (9148)

EcoRI (4183)
KasI (4375)

XmnI (8498)

BamHI (4746)

Kinase Domain

SacI (5075)
EcoRI (5149)
KpnI (6966)

XbaI (5301)

mTOR
XhoI (5515)

FIGURE 5:
Scheme showing a Vector Map of 13,394 bp pCMV6-XL4-mTOR.
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for a tag. A tagged protein as a result of overexpression of the plasmid in mammalian
cells is needed for protein detection and kinase activity studies. Thus, it was first
necessary to subclone the mTOR open reading frame into a plasmid that would
enable detection of the mTOR tagged protein.

For this purpose, we chose the

phCMV2-HA vector that bears the Hemaglutinin epitope tag or “HA tag”. The
mTOR insert was removed, mutated and spliced into a phCMV2-HA vector. The
new vector, with the HA tag allowed for easier identification of the transfected
mTOR.
To establish a baseline purity and concentration the pCMV6-XL4-mTOR was
transformed into DH5α cells. The DH5α cell line is known for its high rate of
transfection efficiency and high plasmid yield and therefore served as a suitable
agent. Using colonies obtained from the pCMV6-XL4-mTOR transfection, cultures
were inoculated for miniprep.

Miniprep colonies were screened by restriction

enzyme digestion for the presence of an insert of the correct length and proper
restriction sites. One colony which had the indications of the proper plasmid insert
was used to inoculate a culture for maxiprep. Using a plasmid prep kit, purified DNA
was extracted from the cell culture.

The plasmid obtained from maxiprep was

quantified and qualified by a 1% agarose gel and spectrophotometry.
Restriction enzyme digestions were performed on the pCMV6-XL4-mTOR
plasmid obtained from the maxiprep. Using the supplied vector map, enzymes were
chosen which would cut the plasmid in pieces large enough to discern if there were
any irregularities between the plasmid which was ordered and that which was
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received. All gel bands that were predicted by the vector map were seen on the 1%
agarose gel (Figure 6).

Mutagenesis
Mutagenic primers were designed to introduce new restriction sites into the
phCMV6-XL4-mTOR plasmid (Table 1). These mutations allowed the restriction
enzyme removal of the mTOR insert from this plasmid and placement into the
pCMV6 plasmid containing the HA tag. Through mutation, the PCR primers added
an additional MfeI site and an additional HindIII site near the promoter region of
mTOR (Figure 7). These additional sites were used to identify the mutated plasmid
during restriction enzyme digestions as well as allow for ligation into the new vector
(Figure 8). The newly mutated plasmid was named pCMV6-mTOR.

pCMV6-mTOR
XL-10 cells from Stratagene were used when transforming the mutagenic
plasmid due to their efficiency in transforming unmethylated plasmids. Next, 26
individual colonies of XL-10 cells transformed with pCMV6-mTOR were selected
from the plates grown overnight (Figure 9). Colonies that showed adequate growth in
liquid broth overnight were selected for miniprep. Restriction enzyme digestion
performed on each of the 26 cultures to verify the MfeI and HindIII sites, indicating
the presence of the mutated plasmid. Additional restriction enzyme digestions were
performed with other carefully chosen pairs of enzymes on miniprep clone number
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Restriction Enzyme Digestion of pCMV6-Xl4-mTOR
FIGURE 6:
Restriction enzyme digestion of pCMV6-XL4-mTOR plasmid purified by
maxiprep from DH5a cells. Lane 1 shows expected banding at 5.2 (two
bands), and 3.0 kb with XhoI digestion. Lane 2 is a BamHI digestion with
bands at 1.0, 1.9, 4.4, and 6.1 kb. Lane 3 digestion shows expected
banding at 9.2, 3.2, and 0.9 kb with EcoRI. Lane 4 is a KpnI digestion
showing the expected banding at 5.9 and 7.4 kb. Lane 5 is 1 Kb DNA
Ladder for reference.

Each digestion revealed the expected banding

indicating the DH5a cells were able to be transformed and could produce
an intact, pCMV6-XL4-mTOR plasmid. The sum of the fragment lengths
in each column equal the total length of the 13.3 kb pCMV6-XL4-mTOR
plasmid. Digestion results were predicted using NEBcutter V2.0 software
avaliable at www.neb.com, and the vector map provided by the
manufacturer of the plasmid.
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pCMV6-XL4-mTOR Mutagenic PCR, Pfu Stratagene

FIGURE 7:
A. Scheme outlining 1-Day Mutagenesis method used to mutaganize
pCMV6-XL4-mTOR to pCMV6-mTOR.
B. PCR map outlining Mutagenic PCR reaction used in mutagenesis of
pCMV6-XL4-mTOR to pCMV6-mTOR.
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CMV promoter

bla promoter

NotI (973)

Amp(R)

EcoRI (980)
MfeI / Hind III mutagenic primer

MfeI (1051)
HindIII (1063)

SV40 ORI

BamHI (1844)

pCMV6-mTOR
NotI (9696)
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FIGURE 8:
Scheme showing a Vector Map of 13,394 bp pCMV6-mTOR.
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23130 bp
9416 bp
6557 bp

13394 bp
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2322 bp
2027 bp

Restriction Enzyme Digestion

FIGURE 9:
Twenty six colonies of pCMV6-mTOR transformed XL-10 cells were
selected for miniprep. Purified DNA was run on a 1% agarose gel to
screen for colonies containing a 13.4 kb plasmid. These colonies will be
subject to a restriction digest to screen for the proper HindIII mutation.
Colonies 9, 16, 24, 25 and, 26 had no plasmid DNA and were excluded
from the restriction enzyme digestion. Colonies 5, 20, 21, 22 and 23 were
suspected to contain a pCMV6-mTOR fragment but would be included in
the restriction digestions because they contain at least some plasmid
DNA.
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three to verify sequences of proper length (Figure 10). This step will prevent using a
plasmid that has an unsuspected deletion.
Using the pCMV6-mTOR plasmid from the miniprep of clone number 3,
DH5α cells were transformed. A robust colony of DH5α cells was again selected
and a maxiprep was performed to obtain a large quantity of pure pCMV6-mTOR.
After maxiprep, the plasmid concentration and integrity of the pCMV6-mTOR
plasmid were verified. A 1% agarose gel revealed a distinct band at approximately
13 kb indicating the presence of proper length DNA (Figure 11).

The

spectrophotometer confirmed the DNA concentration estimate made from the gel, of
300 ng/µl and a DNA purity of 1.994 (A260/280).
The mTOR insert was next removed from pCMV6-mTOR and purified to be
used in ligation. This was accomplished through a HindIII/NotI double enzyme
digestion of pCMV6-mTOR. The addition of the Hind III site in the promoter region
of the mTOR insert and the presence of a NotI site allowed removal of the mTOR
insert from the pCMV6 backbone with a simple double digestion. All restriction sites
were mapped using Invitrogen’s Vector NTI software.
HindIII

The resulting 8633 bp

mTORNotI fragment was visualized on a 1% agarose gel (Figure 12).

Ligation of Hind IIIphCMV2-HANot I and Hind IIImTORNot I
The phCMV2-HA vector with mTOR ligated into allowed for easier tracking
of transfected mTOR for both immunoprecipitation and western blotting because of
the HA tag present in the vector.

This lab has used the phCMV2-HA vector

extensively and has had much success with it.
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Digestion:

pcMV6-mTOR Clone #3
XhoI / HindIII

PspOMI / HindIII

1 Kb

XbaI / HindIII

10 kb
8 kb
5 kb
3 kb
2 kb
1.5 kb
1 kb

0.5 kb

Plasmid:

WT

Mutant

WT

Mutant

WT

Mutant

Restriction Enzyme Digestion
FIGURE 10:
Restriction enzyme digestion of pCMV6-XL4-mTOR and pCMV6-mTOR.
The pCMV6-XL4-mTOR was mutated by the addition of a HindIII
restriction site to give the pCMV6-mTOR plasmid.

Each pCMV6-XL4-

mTOR plasmid is digested with the noted enzymes and run next to the
mutated pCMV6-mTOR plasmid digested with the same enzymes.
XhoI/HindIII double digestion of pCMV6-XL4-mTOR gives the expected
bands at 5.2, 5.2 and 3.0 kb while digestion with the mutant pCMV6mTOR gives 5.2, 3.7, 3.0 and 1.5 kb bands.

The PspOMI/HindIII

digestion of the pCMV6-XL4-mTOR plasmid gives the expected bands at
11.1, 2.0, and 0.2 kb. With the addition of the HindIII site in the mutant
plasmid, the bands as expected are 7.2, 3.9, 2.1, and 0.2 kb. XbaI/HindIII
double digestion also reveals the presence of the additional HindIII site in
the mutant as the W.T. bands are 9.0, 4.3, and 0.1 kb while the mutant
has bands at 4.7, 4.3, 4.3, 0.1 kb.
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6557 bp (100 ng)

Verification of Plasmid Integrity

FIGURE 11:
Verification of pCMV6-mTOR plasmid maxiprep integrity. DH5a cells were
transformed with pCMV6-mTOR and a maxiprep was performed.
Concentration of pCMV6-mTOR purified plasmid was estimated at 300 ng/ml
using l DNA as a reference. Each lane contains the indicated amount of
purified plasmid. For confirmation the plasmid prep (1:10 dillution) was also
quantitated by spectrophotometry at O.D. 260/280:
Concentration = 323 ng/ml
DNA Purity (A260/280) = 1.994
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FIGURE 12:
A. Restriction enzyme digestion of mutated plasmid, pCMV6-mTOR and HAtagged vector. phCMV2-HA vector digested with HindIII and NotI gave a 4.2 kb
band on the gel. These restriction sites are within 60 base pairs of one another
resulting a 4.2 kb band and a small band that was run off the gel. The HindIII
and NotI digestion of pCMV6-mTOR gives the mTOR band at 8.6 kb and the
pCMV6 vector band at 4.7 kb.

Both undigested plasmids also show the

relaxed, coiled and supercoiled states.
B.

After dephosphorylation of phCMV2-HA vector, gel purfication was

performed on pCMV6-mTOR and phCMV2-HA, both double digested with
HindIII and NotI. The double digestion created complementary sticky ends on
both the vector and insert, facilitating their ligation. The 4.7 phCMV6 vector
was discarded, while the 8.6 mTOR insert and the 4.2 kb phCMV2-HA vector
were collected from the gel.
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The phCMV2-HA vector was digested with HindIII and NotI, sites which
were conveniently present in the vector (Figure 12).

The resulting digested vector

was then dephosphorylated to prevent reannealing of the vector onto itself, reducing
the possibility of a looped section of plasmid DNA. After dephosphorylation, the 4.2
kb

HindIII

HindIII

phCMV2-HANotI vector was agarose gel purified alongside the 8633 bp

mTORNotI insert. The phCMV2-HA vector and mTOR inserts were excised from

the gel, and after concentration determination, could be ligated because of
complementary sticky ends.
Next, the dephosphorylated
a 3-fold molar excess of purified

Hind III

Hind III

phCMV2-HANot I vector was combined with

mTORNot I insert. The newly formed plasmid,

named phCMV2-HAmTOR-WT contained a Kanamycin resistant gene which was
used in colony selection and a HA tag which allowed for the tracking of transfected
mTOR (Figure 13).

Transformation into DH5α cells immediately followed the

ligation procedure.

Characterization of the phCMV2-HAmTOR-WT Plasmid
Nine robust colonies of DH5α cells transformed with the ligation reaction
were selected from solid media for miniprep. A miniprep was performed and a 1%
agarose gel confirmed the presence or absence of the undigested plasmid. Colonies
which contained any amount of plasmid were subjected to a double enzyme digestion
to determine the presence of a proper length fragment and the correct orientation of
the mTOR insert into the vector (Figure 14). The phCMV2-HAmTOR-WT double
digestion with HindIII and EcoRV yields bands of 11.3 kb and 1.5 kb in a properly
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CMV+intron

pUC origin
HSV TK polyA

HA

Kan(R)

XhoI (859)
HindIII (868)

SV40 promoter
pAmp

BamHI (1649)
EcoRV (2369)

SV40 polyA

phCMV2-HAmTOR-WT
12832 bp

NotI (9501)

BamHI (3552)

3' UTR

EcoRI (3988)

BamHI (8953)
BamHI (4551)

mTOR
EcoRI (4954)
XhoI (5320)
KpnI (6771)

FIGURE 13:
Scheme showing vector map of phCMV2-HAmTOR-WT designed using
Vector NTI software.
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FIGURE 14:
Double Restriction enzyme digestion of nine colonies of DH5a cells
transformed with phCMV2-HAmTOR-WT.

Enzymes HindIII and EcoRV

were chosen for the double digestion because HindIII is present only in the
properly mutated mTOR insert. The EcoRV restriction site serves as a
way to check the orientation of the insert into the vector. A 1.5 kb band
along with an 11.3 kb band indicated a proper length, properly oriented
plasmid. Therefore, colonies 1 and 9, which have the expected bands at
11.3 and 1.5 kb, were presumed to contain ligated plasmid and were
further examined. Colonies 2, 3 and, 8 were only linearized, indicating
they did not contain one of the restriction sites. The remaining colonies
have other unexpected bands, indicating the ligation was not successful in
those colonies. All colonies except number 1 and 9 were discarded.
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oriented phCMV2-HAmTOR-WT plasmid. Only colonies one and nine contained the
proper bands on the gel and colonies with bands of any other length were discarded.
Purified phCMV2-HAmTOR-WT plasmid from colony nine was selected to
transform DH5α cells. It was determined by the gel that this colony contained a
proper length and properly oriented plasmid.

This colony also had a higher

concentration of plasmid than colony number one, the only other colony which had a
properly oriented and proper length plasmid. This additional transformation step
provides extra assurance that the final plasmid is produced exactly as expected. A
maxiprep was performed on the transformed DH5α cells and purified phCMV2HAmTOR-WT was obtained. Concentration and purity were determined with a
spectrophotometer as well as on a 1% agarose gel. (Figure 15). DNA concentration
was determined to be 400 ng/µl and DNA purity 1.8 (A260/280). Again, restriction
enzyme digestions were performed to confirm the presence of a proper length
plasmid. Digestions with XmnI, BspEI, BamHI, EcoRI/NotI, HindIII/KpnI and
Fsp/MfeI were performed, each reaction verifying the phCMV2-HAmTOR-WT
plasmid (Figure 16).
To further increase the assurance that the generated plasmid is what was
desired, PCR primers were designed against phCMV2-HAmTOR-WT. Two sets of
PCR primers, each targeting a mutation site of the phCMV2-HAmTOR-WT plasmid
were designed online at www.idtdna.com. The lyophilized powder primers were
purchased from Integrated DNA Technologies, Incorporated (Table 3). After PCR
the DNA fragments were run on a 2% agarose gel to confirm purity and proper
length. The remaining volume of PCR mixture was purified and sent for sequencing.
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FIGURE 15:
An agarose gel was used to check the concentration of the 12.8 kb
phCMV2-HAmTOR-WT plasmid after maxiprep. The 13.4 kb phCMV6XL4-mTOR was run as a reference, its concentration was previously
established at 150 ng/ml.

phCMV2-HAmTOR-WT concentration was

estimated at 400 ng/µl. This estimate was verified by spectrophotometry.
Purity was 1.8 (A260/280).
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FIGURE 16:
Restriction enzyme digestions of phCMV2-HAmTOR-WT.
confirmed the proper orientation and size of plasmid.

Digestions

XmnI cuts the

plasmid only once and results in a linearized band at 12.8 kb. BspEI cuts
the plasmid at two sites and results in 6.0 and 6.8 kb bands. BamHI
digestion results in 4 cuts with bands at 5.5, 4.4, 1.9 and 1.0 kb. The
double digestion of EcoRI and NotI results in three bands at 7.3, 4.5 and
1.0 kb. The double digestion of HindIII and KpnI result in two bands,
found at 6.9 and 5.9 kb. FspI and MfeI double digestion result in 3 bands,
found at 6.5, 4.9 and 1.3 kb. The faint banding seen in the FspI/MfeI lane
is likely undigested plasmid as a result of incomplete digestion in that
reaction. Each of the digestions confirms the presence of the phCMV2HAmTOR-WT plasmid in proper orientation and proper length.
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Concentration was estimated and the PCR reactions were sent to Cleveland Genomics
for sequencing. Sequencing confirmed the presence of the point mutations and thus
the successful generation of the HA-tagged mTOR construct, phCMV2-HAmTORWT.

Aim 2: Generate Mutated mTOR Plasmids by Site Directed
Mutagenesis
The newly generated phCMV2-HAmTOR-WT was further mutated to provide
additional valuable molecular tools for the laboratory. Using the same mutagenic
procedures as described in the methods section, point mutations added additional
restriction sites to the phCMV2-HAmTOR-WT construct and gave it different
characteristics.
Previously Jie Chen’s lab described a kinase dead mutant produced by
mutating the Aspartic Acid (D) at position 2357 to a Glutamic acid (E)28. This
mutant gained an additional EcoRI site at that location, and was named phCMV2HAmTOR-D2357E (Table 4).

When analyzed on a gel, a restriction enzyme

digestion of phCMV2-HAmTOR-D2357E with EcoRI would have 3 bands: 8.9, 3.0
and, 1.0 kb. Using New England Biolabs’ NebCutter, at www.neb.com, only 2 bands
at 11.9 and 1.0 kb would be seen with a similar digestion of phCMV2-HAmTORWT.
In 2001 Chen’s lab described a different mTOR mutant, this time a PA
deficient mutant that had its 2109 position Arginine mutated to an Alanine65. This
mutant gained an NruI restriction site and was named phCMV2-HAmTOR-R2109A.
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Plasmid

Mutation Present
Restriction Site
Added
A.A. prior to
mutation
A.A. after
mutation
Mutation Position
Stock
Concentration
Purity (260/280)

phCMV2HAmTORWT

phCMV2HAmTORD2357E

phCMV2HAmTORR2109A

None

Kinase Dead

PA deficient

phCMV2HAmTORS2035T
Rapamycin
Resistant

N/A

EcoRI

NruI

Afl3

N/A

Arganine

Serine

N/A
N/A

Aspartic Acid
Glutamic
Acid
2357

Alanine
2109

Threonine
2035

400 ng/µl
1.8

250 ng/µl
1.83

200 ng/µl
1.81

300 ng/µl
1.69

TABLE 4:
Table indicates the mutations present in the three HAmTOR construct
mutants. Also indicates the sites added, the amino acid that was present
prior to and after mutation, the mutation position and the stock concentration
and purity of the construct. For the purposes of this table, the phCMV2HAmTOR-WT is considered the parental plasmid, and therefore no mutations
are listed.
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The parental phCMV2-HAmTOR-WT plasmid construct does not contain an NruI
restriction site, therefore a restriction digestion of phCMV2-HAmTOR-WT with NruI
results in a linearized plasmid(Table 4).
The earliest described mTOR mutant came from Brown et. al., where the
authors described the mutation of Serine at 2035 to a Threonine, creating a rapamycin
resistant mutant 37. This mutant gained an additional AflIII restriction site and was
named phCMV2-HAmTOR-S2035T (Table 4).

The phCMV2-HAmTOR-WT

construct contains only three AflIII sites, and were seen at 6.0, 5.9 kb and, 882 bp.
The phCMV2-HAmTOR-S2035T construct contains four sites which give observed
bands at 6.0, 5.8, 1.0 kb and, 112 bp.
The well planned mutation of these plasmids with the addition of a new
restriction site provided the advantage of being able to easily identify the mutants. A
simple restriction enzyme digestion was all that was necessary to confirm that the
successful mutation.

However, the mutants were subject to PCR to ensure the

integrity of the plasmid.
The three mutants described were prepared and sequenced in a fashion similar
to the methods used to prepare the phCMV2-HAmTOR-WT plasmid.

Using

phCMV2-HAmTOR-WT as the parental plasmid, PCR primers were carefully
designed at www.idtdna.com to direct point mutations at the chosen sites (Table 2).
These three separate point mutations conferred the desired additional restriction sites
into the DNA. The mutagenesis reactions were then used to transform XL-10 cells,
and those colonies provided the material for a miniprep analysis. After minipreps of
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the three mutant plasmids, restriction enzyme digestions were designed to test for the
presence of the new restriction sites, indicating a successful mutagenesis (Figure 17).
The mutant plasmids were also subject to PCR and sequencing at Cleveland
Genomics. Cleveland Genomics sequencing revealed the successful point mutations
of each of the plasmids, without any unexpected mutations in the DNA. With the
sequence of each of the three mutated plasmids confirmed, and after positively
identifying the additional restriction sites on the restriction enzyme digestion gel we
were able to conclude with certainty that our plasmids could be produced as planned.

Aim 3: Detect Protein Expression of Plasmids by Western Blotting;
Probed with Anti-HA and Anti-mTOR.
COS-7 cells were used for protein expression experiments because they are
capable of expressing large quantities of protein and are easily cultured, even in suboptimal conditions. The COS-7 cell line is from African green monkey kidney cells,
and have a fibroblast morphology. They are adherent to glass and plastic and retain
complete permissiveness for lytic growth of the SV40 viral DNA, a circular DNA
virus of Rhesus Monkey origin. Each of the 4 plasmids generated in this thesis
contain SV40.
COS-7 cells were cultured in T-75 flasks and maintained in 90% DMEM,
10% FBS.

For transfection, the cells were split into 6-well plates (Figure 18).

Multiple products are available commercially for the transfection of adherent cells
including: lipofectin, lipofectamine 2000, Superfect, FuGENE HD and
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FIGURE 17:
The digestion of the phCMV2-HAmTOR-R2109A construct, with its additional
NruI restriction site gives two bands, 8.0, 4.8 kb as opposed to the WT plasmid
which is linearized (12.8 kb) by the single cut of the EcorV enzyme.

The

digestion of the phCMV2-HA-mTOR-D2357E construct shows the addition of an
EcoRI site by the presence of the expected four band pattern shown: 7.2, 2.9,
1.6 and, 0.9 kb. The phCMV2-HAmTOR-WT plasmid was cut only three times,
giving expected banding pattern of 10.2, 1.6 and, 0.9 kb. The digestion of the
phCMV2-HA-mTOR-S2035T plasmid gives the banding pattern 6.0, 4.5, 1.3, 0.9
and, 0.1 kb due to the presence of an additional AflIII site. The 113 bp band
was run off the gel, but it is clear that the additional AflIII site is present due to
the change from the phCMV2-HAmTOR-WT band of 1.4 kb to the mutant
phCMV2-HAmTOR-S205T which shows a 1.3 kb band.

The phCMV2-

HAmTOR-WT plasmid banding shows the expected pattern of 6.0, 4.4, 1.4 and,
0.9. All banding patterns were predicted with NEBcutter 2.0 at www.neb.com.
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Start with Cos-7
cells in DMEM
+ 10 % FBS
(No antibiotics)

DAY 0

DAY 1

DAY 2

Harvest
Cells

Aspirate media and
add OptiMEM
to cells

Combine DNA plasmid
with Lipofectamine &
Plus in OptiMEM

Add transfection
agents to cells

3 hour incubation

Aspirate OptiMEM and
add new DMEM + 10%
FBS

FIGURE 18:
Scheme

outlining

protocol

for

transfecting

COS-7

cells

using

Lipofectamine and PLUS reagents to allow for the overexpression of HAtagged mTOR.
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Lipofectamine-Plus combination. The combination of Lipofectamine and Plus was
chosen because the lab had previous success with those agents.
Dose response experiments were carried out to establish the amount of each
plasmid that was required for an effective transfection of the COS-7 cells. For these
experiments each of the four plasmids were transfected in different plates. The
phCMV2-HAmTOR-WT plate had wells with increasing amounts of plasmid as
follows: 0.0, 0.5, 1.0, 1.5, 2.0 and, 3.0 µg. Each of the mutant plasmids were also
transfected in their own plate with an increasing amount of plasmid identical to the
phCMV2-HAmTOR-WT plate. The transfection reactions were allowed to precede
for three hours after which time the cells were washed and incubated for another 48
hours in DMEM + 10% FBS media. Cell lysates were harvested using lysis buffer
described in methods and a cell scraper to remove the adherent cells from the plastic
culture wells.
Additionally, time course experiments were performed to determine the
optimal time for harvest of transfected COS-7 cells (Figure 19). Transfections were
performed with the phCMV2-HAmTOR-WT plasmid and compared with mock
transfections.

Lysates were harvested at 0 hours (immediately after 3 hour

transfection incubation), 15, 24, 48 and 72 hours. The lysates obtained after a 72
hour incubation had the highest concentration of total protein. An increase in total
protein has been interpreted as an indicator of cell growth. While these two can not
be absolutely conclusively linked, thymidine experiments in our lab have given
evidence to conclude an increase in protein concentration is linked to cell growth.
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ng/µl Total Protein

TIME COURSE EXPERIMENT

Time (Hours)

FIGURE 19:
COS-7 cells were transfected with either phCMV2-HAmTOR-WT or subject to
a mock transfection. The cell lysates were then harvested at 0, 15, 24, 48 or,
72 hours.

The zero hour lysate was taken immediately after the 3 hour

transfection incubation. The black bars represent a mock transfection, the
gray bars represent transfection with the phCMV2-HAmTOR-WT plasmid
DNA. An increase in total protein has been interpreted as an indicator of cell
growth.

This interpretation has been verified in our laboratory through

thymidine incorporation experiments. Cell lysates taken at 72 hours had a
moderate percentage of dead cells, and a noted morphology change. Cell
viability studies conducted by our lab have routinely shown a rapid decrease
in cell viability 48 hours post-transfection. For this reason, lysates for this
thesis were taken at 48 hours post transfection.
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There was a higher cell death rate in the cultures allowed to incubate for 72
hours. Also, by 72 hours post transfection there was a noted morphology change in
some of the cells in the culture. As a result, we determined that by 48 hours the cells
had produced an adequate amount of protein for our experiments and had a consistent
morphology.
Protein concentration determination was carried out using a commercially
available protein assay solution.

This concentration determination provided the

necessary information to normalize the samples for SDS PAGE and Western Blot.
After the samples were normalized to a standard quantity of protein, SDS-PAGE gels
were run. The embedded proteins were transferred to a PVDF membrane and a
Western blot was performed (Figure 20).

Western blots consistently showed

transfection with 2 µg of plasmid as optimal for maximum protein expression (Figure
21).

Using 2 µg of plasmid DNA resulted in a four fold increase in protein

expression over mock transfections.

AIM 4: Determine Enzyme Activity of Overexpression Plasmids
using KLISA, Mass Spectrometry, or [32P] γ−ATP to detect
phosphorylation of mTOR substrates.
We used a commercially available mTOR kinase assay to determine kinase
activity of the overexpressed HA-mTOR (Figure 22). While there are a small number
of articles which report some data while using a commercially available kit, this lab
enjoyed little success with the product. Various experimental conditions were used,
and various data interpretation techniques were employed in an effort to elucidate

70

230 kDa

116 kDa

116 kDa

86 kDa

86 kDa

44 kDa

44 kDa

32 kDa

32 kDa

µg
2.
0

µg

r
M

230 kDa

0

ke
ar

µg

B.

2.
0

µg
0

M

ar

ke

r

A.

16 kDa

16 kDa

Probed with
Anti-mTOR

Probed with
Anti-HA

FIGURE 20:
A. Western Blots were probed with anti-mTOR and developed on X-ray
film using the Kodak ECL method.

This experiment used cell lysates

transfected with 2 mg of phCMV2-HAmTOR-D2357E plasmid DNA or a
mock transfection. Sonicates were taken and 600 ng total protein was
loaded into each lane of the gel. The PVDF was probed with the primary
antibody Anti-HA and the secondary antibody, Anti-mouse. In the mock
transfection lane, a faint band representing endogenous mTOR can be
observed at 289 kDa, noted by the red arrow.

The endogenous and

exogenous mTOR is represented by the darker band at 289 kDa in the
lane with lysate from cells transfected with phCMV2-HAmTOR-D2357E.
B.

Probing the blots with Anti-HA, we were able to visualize the

exogenous mTOR only. Thus in the mock transfected lane, there was no
band because there was not any HA tag in that lysate.

In the 2 mg

transfected lane, the band representing the transfected HA-mTOR can be
visualized, again noted by the red arrow. In subsequent experiments the
Anti-HA probe was used in order to detect only exogenous mTOR.
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FIGURE 21:

Lysates were used for Western Blot analysis to determine protein expression
of each of the constructs. The films above depict the transfection of the
noted amount and type of plasmid DNA. The gels were probed with Anti-HA
and Anti-mouse HRP. The indicated 289 kDa band represents the HAmTOR
present in each condition.
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mTOR ELISA Based Assay
1. Obtained COS-7 Lysates
2. Supplied mTOR substrate
binds to solid support of
Glutathione-coated 96 well
plate

Glutathione-Coated 96 well plate

3. Incubated 50 ml mTOR
lysate with 50 ml supplied
Kinase Assay buffer and ATP in
96 well plate
4.
Active mTOR was
phosphorylated p70S6K at
Thr389
5. Phosphorylated substrate
was detected with Antip70S6K-T389
antibody
followed by HRP-Antibody
Conjugate and TMB substrate
6. Absorbance was read at
450 nm in Biotrak II Visable
Plate Reader

FIGURE 22:
The commercially available mTOR activity Kit is an enzyme linked
Immunosorbent assay (ELISA). It relies on the phosphorylation of p70S6KGST fusion protein as its indicator of mTOR activity. The phosphorylation is
detected by Anti-p70S6K-T389 antibody followed by detection with HRPantibody conjugate and TMB substrate. The relative activity of the mTOR
was determined by the absorbance at 450 nm as determined by a Biotrak II
Visable Plate Reader.

The manufacturer's protocol was followed for all

steps of the assay.

73

reproducible data while using the kit. A calibration was performed using the supplied
mTOR standard and different types of water to ensure the pH of the samples did not
effect the kit (Figure 23). Calibrations revealed data that modeled the manufacturers
standard curves, but with absorbance values that trended much lower than the
manufacturers data.
The data we obtained with the KLISA mTOR kit revealed a 2.6 fold increase
in mTOR activity of the 1 µg W.T. plasmid transfected cells over mock transfections.
Transfections with 2 µg of the W.T. plasmid revealed a five fold increase in mTOR
activity. However this data was not reliably reproducible and measured absorbances
often varied widely (Figure 24).
A literature review was conducted and revealed that other labs previously had
difficulty with the commercially available mTOR kits. Several kinase assay recipes
were found, and a suitable one was modified for use. The 2X Kim Kinase Buffer was
used in combination with a Mass Spectrometer to obtain kinase activity data from the
COS-7 cell lysates transfected with each of the 4 created plasmids. COS-7 lysates
were incubated with 2X Kim Kinase Buffer and prepared on a spectrometer protein
chip.

The phosphorylated proteins should have been discernable from the non-

phosphorylated proteins by the 80 Dalton increase in molecular weight.
The cell lysate and Kinase assay buffer were incubated with active and
inactive versions of p70S6 Kinase as well as 4E-BP1. As discussed earlier, both are
known downstream phosphorylation targets of mTOR. A calibration with Bovine
Serum Albumin (BSA) was performed to determine the sensitivity of such an
experiment (Figure 25). Unfortunately it was soon suspected that the amount of
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mTOR KLISA Kit Calibration
A.

y = -0.0012x2 + 0.0507x + 0.0676
R2 = 0.9777

Absorbance, dH20
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0.1

B.

1

Absorbance. Ultrapure MB H2O
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100

y = -0.0013x2 + 0.0511x + 0.0491
R2 = 0.9898

0.6
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0.4
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C.

1

Absorbance, RNA'se Free H20
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y = -0.0011x2 + 0.0492x + 0.0547
R2 = 0.9938
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10

100

FIGURE 23:
mTOR KLISA kit calibrations. Each of graphs represents a calibration of the
KLISA kit, using different types of water with the mTOR standard supplied with
the kit. A dilution series was made up using 0.0, 0.5, 1.0, 2.5, 5.0, 10.0, 25.0
and 50.0 ml of mTOR standard, the specified type of water was used to bring
the total reaction mixture to 50 ml. The Y-axis lists measured absorbance, the
X-axis represents the amount (in ml) of water present in the sample. Each of
the graphs was fit with a polynomial regression line with the lowest R2 value of
0.97.
A. Water from distilled water tap on the lab bench.
B. Molecular Biology Grade, Ultrapure RNA'se free water supplied from USB.
C. RNA'se free water supplied from Qiagen.
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mTOR Activity
(Arbitrary Units)

A.

µg transfected phCMV2-HAmTOR-WT

B.
Lysate #
1
2
3

COS7 Transfection
Mock 0.0
1.0 µg WT
2.0 µg WT

Abs 450
0.161
0.165
0.182

Units
12.636
16.273
31.727

ng/rxn
4.203
4.229
2.102

U/ng
2.988
7.741
15.093

FIGURE 24:
Kinase activity as determined by mTOR KLISA kit.
A. The graph shows mg of phCMV2-HAmTOR-WT used for the transfection
on the X-axis. The Y-axis is the units of mTOR activity. Units of mTOR
activity were defined arbitrarily, by comparing the experimental values to
those obtained from the supplied mTOR standard.
B. The chart defines the paramaters used to construct the graph. Lysate
number was assigned for tracking purposes. COS-7 transfection details the
amount of plasmid DNA used to transfect the condition. Abs 450 is the raw
data obtained from the visable plate reader. Units is a relative measurement
of mTOR activity compared to a ml quantity of mTOR standard supplied with
the kit. This relative number takes into account the amount of DNA in each
sample and the corresponding amount of mTOR actvity. The standard curve
generated an equation of Y = 0.0011x + 0.1471. This equation was used to
obtain the Units value for the chart. The amount of protein per condition is
listed as ng/rxn. The value of Units/nanogram is listed last and shows the
mTOR activity per nanogram of total protien.
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MASS SPECTROMETRY
BSA Calibration

FIGURE 25:
A Bovine Serum Albumin (BSA) calibration was performed to insure the
mass spectrometer was functioning properly and could detect proteins at
different concentrations. BSA, a 66 kDa protein could be easily detected
above the 10 ng quantity, but detection below that quantity was poor. The
chart shows the peaks seen when a protein chip was run with the quantity
of protein noted on the right side of the chart.
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glycerol in the kinase mixture was too great, inhibiting the detection of the small
quantities of protein. The chip which the kinase assay was run on often did not dry
out enough for the mass spectrometer to read it. Therefore, the chips often sat in a
37°C oven overnight or in some cases, over the weekend in an attempt to dry them.
After the chips were dried, the spectrometer revealed no peaks that could be
reasonably linked to this experiment (Figure 26). Therefore, no conclusive results
could be obtained. The expected shift could not be visualized, and in some cases, no
protein could be detected. Various adjustments to Kim’s Kinase buffer were unable
alleviate the difficulties encountered with this method of kinase assay.
A third kinase assay was developed using radiolabeled [32P]γ−ATP (Figure
27). This assay was adapted from Kim et. al. and designed to avoid some of the
difficulties the previous assays posed10. COS-7 cell lysates were taken as described
in Methods, and an immunoprecipitation was performed with HA-agarose beads in an
effort to concentrate the transfected mTOR. This assay used the 4X Kim Kinase
Buffer and the immunoprecipitation reactions were incubated with either p70 S6
Kinase or 4E-BP1 protein. Experiments with p70 S6 Kinase (T412E), an active
kinase, revealed a large amount of autophosphorylation.
The ability of p70 S6K to autophosphorylate covered the phosphorylation that
was expected by mTOR (Figure 28). The kinase reaction using 4E-BP1 enjoyed
more success, in part because 4E-BP1 does not have any autophosphorylation
abilities (Figure 29).

This assay shows the ability of mTOR to incorporate

[32P]γ−ATP into 4E-BP1. Lysates from COS-7 cells were used for the 4E-BP1 kinase
reactions. These kinase reactions were run on SDS-PAGE gels and transferred to
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MASS SPECTROMETRY KINASE ASSAY
A.

B.

C.

D.

E.

FIGURE 26:
The mass spectrometry kinase reaction did not reveal any discernable
peaks.
A. Kinase reaction with no 4E-BP1, to get a baseline.
B. 4E-BP1 and [32P]g -ATP incubated with lysate from mock transfection.
C. 4E-BP1 and [32P]g -ATP incubated with lysate from transfection with
phCMV2-HAmTOR-WT.
D. 4E-BP1 and [32P]g -ATP incubated with lysate from transfection with
phCMV2-HAmTOR-D2357E.
E. 4E-BP1 and [ 32 P]g -ATP incubated with mTOR standard that was
supplied with commercially available mTOR kinase assay kit.
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[32P]g-ATP Kinase Assay
mTOR
γ−ATP

32

32
γ−ATP

ADP

ADP

P

4E -B P 1

P

S 6K
eIF 4E
48.7 kDA
Phospho-S6K

21 kDA
Phospho-4E-BP1

FIGURE 27:
An mTOR kinase assay was developed using [32P]g-ATP to detect
phosphorylation of the known substrates, p70 S6K and 4E-EBP. Lysates
of COS-7 cells transfected with the HA-mTOR plasmids were incubated
with 5 mci of [32P]g -ATP and one of the substrates. The kinase reaction
was incubated for 20 minutes and then run on an SDS-PAGE gel. The
proteins in the gel were transfered to a PVDF membrane which was then
exposed to X-ray film.
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[32P]g-ATP Kinase Assay
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FIGURE 28:
X-ray film shows kinase assay using [32P]g-ATP.

COS-7 cells were

transfected as indicated and lysates used in kinase assay. This assay
used p70 S6 Kinase (T412E) active, as the substrate. mTOR is known to
phosphorylate the 48.7 kDA downstream target, p70 S6k.

We were

expecting mTOR to encorporate the [32P]g-ATP into the p70 S6K and the
degree of phosphorylation would be detected by the intensity of the band
on the film. However in this experiment, all the lanes, including the mock
transfection and the lane with no lysate showed phosphorylation. We now
hypothesize that the active p70 S6K autophosphorylated and covered any
mTOR phosphorylation of the kinase. When the experiment was repeated
with heat denatured p70 S6K to render the kinase inactive, no
phosphorylation of any type was observed.
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[32P]g-ATP Kinase Assay
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FIGURE 29:
X-ray film showing kinase assay using [32P]g-ATP.

This assay used

protein 4E-BP1 as the substrate. mTOR is known to phosphorylate the
21 kDA downstream target, 4E-BP1.

This protein is not able to

autophosphorylate and provided a more accurate picture of the kinase
activity of mTOR.

The first lane is lysate taken from COS-7 cells

transfected with phCMV2-HAmTOR-WT. The second lane is lysate taken
from a mock transfection. The mock transfection shows some mTOR
activity because of the endogenous mTOR present.
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PVDF membranes.

These membranes with the proteins, and incorporated

[32P]γ−ATP were then exposed to X-ray film (Figure 30).

Once the film was

developed, ImageGauge V.4.0 software was used to quantify the band strength of the
phosphorylated protein (Figure 31).
The ImageGuage software revealed a 13 fold increase in phosphorylation of
4E-BP1 with the phCMV2-HAmTOR-WT plasmid over a mock transfection.
Additionally the Kinase Dead mutant, phCMV2-HAmTOR-D2357E had a 4 fold
increase in phosphorylation. The two other plasmids, phCMV2-HAmTOR-R2109A
and phCMV2-HAmTOR-S2035T showed still larger increases in phosphorylation of
4E-BP1 when overexpressed in COS-7 cells.
This third kinase assay had the most success of the three assays.
Phosphorylation of the two substrates could be detected, but phosphorylation levels
varied. Several changes were made in the technique used to incubate the kinase
mixture, and the amount of [32P]γ−ATP used in the reaction was varied.

The

difficulty of obtaining mTOR kinase data does not come completely as a surprise
however.
Researchers hypothesize that because of the large mulitmeric structure of
mTOR, that the processing of mTOR for kinase assay can interrupt these
interactions10. The roles that these additional proteins play is largely unknown, but
suspected to mediate kinase activity and mTOR function.

Ongoing studies to

establish more firmly the in vivo protein to protein interactions is essential to the
understanding of mTOR. Until then, reliable kinase data may be unattainable.

83

St
d.

TO
R

T.F
.
m

Mo
ck

HA
-m
T
D2 OR
35
7
R2 E
10
9A
S2
03
5T

Kinase Assay
Substrate: 4E-BP1
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FIGURE 30:
The kinase reaction using 4E-BP1 and [32P]g-ATP was analyzed using Fuji
ImageGauge V.4.0. A reference area was obtained for each band and is
noted as a black oval on the gel. The relative density of this oval was
measured with the software. An oval of the same area, in red, was then
used to measure the relative density of the 21 kDa 4E-BP1
phosphorylated band. The reference density was then subtracted from
the band density to obtain a relative density indicating the amount of
phosphorylated 4E-BP1 present in the sample.
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mTOR ACTIVITY

Relative Density of Phospho-band
(Arbitrary Units)

Densitometry of Phospho-4E-BP1

Transfected Plasmid

FIGURE 31:
Relative Density for each sample from the previous figure. The mTOR
standard was supplied with the mTOR KLISA kit and was run to determine
if the standard contained any active mTOR. Its relative value should be
considered alone and not compared to that of the other samples.
Transfection with 2 µg of phCMV2-HAmTOR-WT yielded a relative density
of 2.63.

Transfection with D2357E gave a relative density of 0.79.

Transfection with R2019A gave a relative density of 4.43. Transfection
with S2035T gave a relative density of 8.00. A mock transfection yielded a
density of 0.20. The mTOR standard resulted in a relative density of 4.7.
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AIM 5: Investigate the effects of mTOR Transfection on Gene
Expression and Sub-cellular Localization
Gene Expression
Real Time PCR is a tool which has a high sensitivity to small amounts of
DNA and is generally more accurate than traditional PCR.

This tool allowed

investigation into the molecular workings of the cell. Using the computer generated
Ct values the gene fold of a mock transfection could be compared to that of cells
transfected with plasmid DNA. Gene fold is a relative measurement of the greater
number of copies cDNA are produced during a PCR reaction.
RT-PCR relies on the fluorescence of a probe attached to a primer designed
against a gene of interest (Figure 32). Taqman gene expression probes were obtained
for these experiments from Applied Biosystems, Foster CA. These probes were
designed against the sequence of interest: mTOR, S6K and PLD2. The probe is
bound just downstream of the primers, near the target sequence.

When the

polymerase reaches the 5’ end of the probe, the fluorophore, attached at the 5’ end of
the probe is released. Once the flourophore is released, it is free of the inhibitory
effects of the 3’ quencher molecule. It is this separation that causes the fluorescence
which is subsequently detected by the Real Time PCR machine. The intensity of
fluorescence is increased as the number of DNA template increases, and more
flourophore’s are released.
Lysate from COS-7 cells transfected with plasmid DNA were obtained and
RNA was extracted from the lysates with a Qiagen RNeasy Kit. RNA was quantified
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QRT-PCR CHEMISTRY

Detection
FIGURE 32:
Scheme outlines Real Time PCR chemistry using the Taqman probes.
Taqman DNA polymerase moves in a 5' direction toward the Taqman
probe. The exonuclease activity of the polymerase causes the release of
the flourescent dye into the solution.

With the release of the dye the

quencher can no longer mask the signal of the flouophore. The increase
in flourescence is detected during the exponential phase of the PCR
reaction. Obtaining data at the exponential phase of the PCR reaction is
a more accurate and reproducible method of obtaining gene fold data.
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against an RNA standard using Molecular Probe’s Ribogreen RNA Quantitation Kit.
An equal amount of RNA from each condition was reverse transcribed to cDNA.
After cDNA was obtained, RT-PCR could be carried out. For this thesis each of the
transfection conditions from which the cDNA was obtained were incubated with the
mTOR PCR probe. This allowed the detection of mTOR in all the transfection
conditions (Figure 33).
Using the Ct value which was calculated by the PCR computer, the gene fold
could be calculated for each of the experimental conditions. The fluorescence of the
mTOR probe is compared against the fluorescence of a housekeeping gene, in this
case glucuronidase. This ∆Ct value was then compared against the mock transfection
to normalize the data. This ∆∆Ct value is then used in the equation y=2(-∆∆Ct) where y
is the gene fold97. This calculation gives a relative value of the amount of mTOR
cDNA present in the sample.
Our data shows that transfection with the mTOR plasmid DNA constructs
does in fact significantly increase the gene fold of a sample (Figure 34). We detected
a 170 fold increase in mTOR gene expression using our phCMV2-HAmTOR-WT
plasmid.

Additionally, the kinase dead phCMV2-HAmTOR-D3457E plasmid

showed a 160 fold increase in gene expression. The Myc-PLD2 plasmid, when
lysates were probed for mTOR gene expression, showed only negligible change.

Immunoflourescence Microscopy
Immunoflourescense images were obtained to visualize the localization of the
transfected mTOR (Figure 35). These images were obtained after transfecting COS-7
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FIGURE 33:
Real Time PCR was used to determine the increase in gene fold after
transfection with a DNA plasmid. The graph shows a typical readout from the
RT-PCR machine. The purple horizontal line represents the Ct value,
calculated by the RT-PCR machine. A smaller Ct value represents a higher
cDNA expression, and thus larger gene fold. All conditions were probed with
the mTOR probe. Thus the relative amount of mTOR in each sample was
examined. The lysates transfected with phCMV2-HAmTOR-D2357E,
phCMV2-HAmTOR-WT and, pCMV6-XL4-mTOR each have a relatively high
mTOR gene fold, as would be expected. The mock transfection and myc
PLD2 have lower mTOR levels as they are only expressing basal mTOR.
The no DNA template control is run to ensure the validity of the data and
shows no amplification until the end of the PCR reaction.
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GENE FOLD ANALYSIS

Transfection Condition
mTOR(FAM)
Gluc (TexRed)
∆Ct
∆ ∆ CT
2^(- ∆ ∆ CT) "Gene Fold"

Mock T.F.
22.01
23.07
-1.06
0

1.0

HAmTOR WT
14.49
22.96
-8.47
-7.41

170.1

pCMV6-XL4-mTOR
18.09
26.87
-8.78
-7.72

210.8

phCMV2-HAmTOR-D2357E
14.12
22.5
-8.38
-7.32

159.8

Myc-PLD2
22
23.66
-1.66
-0.6

1.5

FIGURE 34:
Using the DDCt value, gene fold for each of the transfection conditions can
be calculated. The DCt value is calculated by subtracting the Ct value of
the gene of interest from the Ct value of a housekeeping gene,
glucuronidase. This DCt value is then subtracted from the mock
transfection to normalize the samples to obtain a DDCt value. Finally the
DDCt value is used in the equation 2-DDCt to obtain gene fold. This data
shows a 170 times increase of the mTOR gene in the phCMV2-HAmTORWT transfected lysates compared to the mock transfection. The pCMV6XL4-mTOR plasmid showed a 210 times increase in mTOR gene
expression. Similarly phCMV2-HAmTOR-D2357E showed a 160 times
increase. The lyastes from Myc-PLD2 transfected cells showed no
increase in mTOR gene expression.
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A.

phCMV2-HAmTOR-WT

B.

C.

Mock Transfection

D.

FIGURE 35:
COS-7 Cells transfected with phCMV2-HA-mTOR-WT (A and B) or a Mock
Transfection (C and D). The polymerized Actin in the cell is stained red with
Phalloidin TRITC dye containing a Rhodamine tag. The DNA is stained
blue by a DAPI dye. The flourescent green color is the transfected mTOR,
tagged by the anti-HA FITC antibody conjugate. The mTOR has a
perinuclear distribution, and none was observed in the nucleus or around
the plasma membrane. The punctuate dots of mTOR are likely endosomal
vesicles.
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cells with phCMV2-HAmTOR-WT or a mock transfection. The images show indeed
transfected mTOR was able to enter the cells as endogenous mTOR is not seen.
The polymerized actin, a structural protein, was dyed red with PhalloidinTRITC containing a Rhodamine tag. The DNA was stained blue with a DAPI dye in
order to visualize the nucleus of the cell. The transfected HA-mTOR fluoresced
green after it was incubated with conjugate an anti-HA FITC antibody. No mTOR is
seen within the nucleus as this would appear as a yellow or orange color on the
images.
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V. CONCLUSIONS
1. Previous studies have lacked a reliable means of overexpressing mTOR in
mammalian cells.

2. We have developed four phCMV2-HA-tagged mTOR plasmids: Wild Type,
D2357E (Kinase Dead), R2109A (PA Binding Deficient) and S2035T
(Rapamycin Resistant). Each one has 12,832 base pairs, and all were verified
by restriction enzyme digestions and direct sequencing.

3. Plasmid DNA was overexpressed in COS-7 cells and the mTOR protein of
289 kDa was found in Western Blots developed with anti-HA or anti-mTOR.
The overexpressed protein showed a four fold increase over the endogenous
mTOR.

4. Kinase activity of the overexpressed protein was measured by
phosphorylation of 4E-BP1 and S6K.

Lysates of cells transfected with

phCMV2-HAmTOR-WT had a 13 fold increase in 4E-BP1 phosphorylation
over the mock transfected cells. The Kinase Dead mutant had only a 4 fold
increase in kinase activity over the mock. The R2109A and S2035T mutants
had a 22 fold and 40 fold increase, respectively, over the mock transfections.

5. mTOR gene expression was elevated over that of the mock transfections as
detected by QRT-PCR. Cells transfected with the phCMV2-HAmTOR-WT
plasmid DNA had a 170 fold increase in mTOR gene expression over mock
transfected cells.

The Kinase Dead mutant showed a similar 160 fold

increase. However, gene expression of PLD2 was not effected by the over
expression of mTOR.
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6. Subcellular localization by immunoflourescence indicated that mTOR is
concentrated in perinuclear space and none was observed in the nucleus or
near the plasma membrane . We hypothesize that mTOR is concentrated in
endosomal formations near the nucleus for use in translation regulation.

7. This study provides important molecular biology tools for this lab’s continued
investigation into the crosstalk between mTOR, S6K, PLD1 and PLD2.
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VI. DISCUSSION
The results presented in this thesis fall within the overall study of four signal
transduction molecules: mTOR, S6K, PLD1 and PLD2 and their interaction in a
living cell. The work to generate and characterize an HA-tagged mTOR construct has
provided the lab with another method of investigating these important pathways.
Previously studies have focused on work with siRNA technology and a new
electroporation method to deliver DNA to the cell nucleus. Tabatabaian, M.S., was
successful in using these technologies to show that cells transfected with si-mTOR
and si-S6k often had a PLD2 gene expression of several hundred times the basal rate.
The new HA-tagged mTOR plasmid constructs allow for mTOR overexpression and
the subsequent study of the effect of mTOR overexpression on S6K and PLD which
was lacking in the previous study.
The first two aims of this thesis were accomplished through the preparation of
the HA-tagged plasmid, phCMV2-HA-mTOR and subsequent point mutations of the
parental plasmid to obtain the mutated HA-tagged plasmids. These four plasmids
were characterized through restriction enzyme digestions and were sequenced by
Cleveland Genomics.

They were transfected into mammalian cells with a high

efficiency, and cell lysates from those tranfections supplied the raw material for the
remainder of the experiments in this thesis.
Protein expression of the HA-tagged mTOR was accomplished by transfecting
the mTOR plasmids into mammalian COS-7 cells. COS-7 cells were chosen because
of their ease of transfection and ability to produce large amounts of protein. Lysates
were obtained, SDS-PAGE gels run and the proteins were transferred to a PVDF
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membrane. Western Blotting with anti-HA and anti-mTOR was able to detect the
expression of mTOR. We concluded that 2 µg of plasmid DNA was adequate to
transfect one well of a six well plate of COS-7 cells at 70% confluency. Using a
greater quantity of plasmid for transfection seemed to negatively affect the cells,
resulting in more cell death and greater morphology changes before the lysates were
harvested at 48 hours after transfection.
During protein expression experiments, we experienced a variability in the
amount of total protein that each six well produced. This variability may have been
due to the cell harvesting techniques, effectiveness of the lysis buffer or, simply a
result of the variability that is inevitably expected in dynamic biological systems. To
prevent this variability and to increase the confidence in the protein differences
between samples, larger wells or multiple wells for each condition should be used,
and the lysates combined. This provides for a larger amount of protein to work with
and reduces the variability associated with any live cell experiment.
Various mTOR kinase assays were attempted to show the activity of the WT
plasmid compared to the mutated plasmids. We were able to show through the
phosphorylation of 4E-BP1, that the overexpressed plasmids increased the
phosphorylation of the downstream target compared to a mock transfected lysate.
The data shows a 13 fold increase in 4E-BP1 phosphorylation with phCMV2HAmTOR-WT transfected lysates versus the mock transfected lysates. Additionally,
the Kinase Dead plasmid, phCMV2-HA-mTOR-D2357E, had only a four fold
increase in phosphorylation over the mock transfections. This is directly in line with
the approximately 60% reduction in kinase activity published by Park, et. al.41.
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mTOR kinase assay data is scarce in the published literature, but those authors
that do publish results often report variability in kinase activity, similar to what we
experienced. It is thought that the variability is a result of the many protein to protein
interactions that regulate the activity of mTOR10. The loss of one or more of these
associated proteins during the lysate isolation process may effect the ability of mTOR
to remain as an active kinase for an in vitro assay.
There are several pieces of evidence that support the missing protein theory.
The first is that mTOR contains HEAT repeats, described in the literature review of
this thesis. These HEAT repeats are known to be protein to protein interaction
domains.

These HEAT domains may form an extended superhelical structure,

creating multiple large interfaces for proteins to interact98. Second, in gel filtration
chromatography, mTOR migrates at a disproportionately large apparent molecular
weight of 1.5 to 2.0 mDa10. While this phenomenon was not observed during our
experiments, this data suggests a close association between mTOR and other protein.
mTOR is known to be sensitive to several standard lysate treatment solutions.
Non-ionic detergents such as Triton X-100 and NP40 should not be used because they
inactivate mTOR99. Cell lysis buffers for this thesis included Tween-20, which does
not cause the same dissociation as the non-ionic detergents. Also, mTOR is sensitive
to phosphate containing buffers and therefore PBS should not be used99.

This

sensitivity was not understood until just a few years ago, and much of the literature
published before 2003 report using PBS in their kinase assays 83. mTOR also requires
Mn2+ for activity, which was included in our kinase assay buffers.
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The [32P]γ−ATP kinase assay was the only assay that we used that produced
repeatable mTOR kinase activity data.

We showed the ability of mTOR to

phosphorylate 4E-BP1 and analyzed the data using Fuji ImageGauge V.4.0. Our
kinase dead mutant, phCMV2-HAmTOR-D2357E, showed less than half the activity
of the phCMV2-HAmTOR-WT plasmid.

The two other mutants, R2109A and

S2035T showed a higher kinase activity than the WT plasmid. The [32P]γ−ATP
kinase assay using p70 S6K as a substrate did not provide the same results. We
hypothesize that the autophosphorlyation capabilities of p70 S6K inhibited our ability
to discern what effects mTOR had on this downstream molecule. Interestingly, when
p70 S6K was heat inactivated in an effort to prohibit its autophosphorylation
capabilities, no mTOR kinase activity was observed.
Futher studies on the intricate interactions between mTOR and its associated
proteins are needed in order to study kinase activity. Too little is known even about
the structure of mTOR to assert that each of its domains is fully understood. These
domains play an important role in protein to protein interactions which may modify
the activity of mTOR.

Studies need to focus on associated mTOR proteins as

important modulators of mTOR activity such that a reliable kinase activity assay can
be developed without concern of loss of activity due to disruption of these proteins.
Real time PCR has proven itself as a reliable tool for investigating gene
expression at the earliest detectable time in the cell; cDNA expression.

Our

experiments showed that each of the HA-tagged mTOR plasmids were able to
increase the amount of mTOR cDNA being transcribed in the transfected cells.
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Gene folds of phCMV2-HAmTOR-WT transfected cells increased 170 fold
over that of the mock transfected cells. Similarly the Kinase Dead D2357E plasmid
had a gene fold of 160 times the mock. For this experiment we expected a similar
increase in gene expression with each of the plasmids. Although the D2357E mutant
has a reduced kinase activity, the cDNA copies of the gene are still made at an
increased rate over the mock transfections.

The pCMV6-XL4-mTOR plasmid

obtained from OriGene had a gene fold increase of 210 times the mock transfection.
When a Myc-PLD2 plasmid was used to overexpress PLD2, no change in mTOR
gene expression was detected.
Our data showed no significant change in PLD1, PLD2 or S6K expression
with the overexpression of mTOR using the HA-tagged plasmids. This lab has
previously shown that mRNA expression of PLD2, mTOR and S6K are coordinately
regulated. In her thesis, Tabatabaian, M.S., showed that transfecting dHL-60 cells
with si-mTOR and si-S6k caused PLD 2 gene expression to rise dramatically96. The
data that we have does not show the opposite to be true. The overexpression of
mTOR using HA-tagged mTOR constructs does not seem to increase PLD2 gene
expression. However, more studies need to be completed to confirm this hypothesis.
Studies should include rapamycin and wortmanin, known inhibitors of mTOR.
Additionally experiments adding growth factors to attempt to upregulate mTOR
should be attempted.
Finally, fluorescence images were obtained of COS-7 cells transfected with
HA-mTOR. These images provided confirmation that mTOR is a cytosolic protein,
localized very near the nucleus. These findings agree with Liu et al. who published
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findings stating that mTOR had unusual endoplasmic reticulum and Golgi apparatus
targeting sequences in its HEAT domain100. The location of the transfected mTOR
may be due to the fact that mTOR is shuttled in and out of the nucleus in order to
interact with S6K101. However, no mTOR was observed within the nucleus. This
may be explained by the fact that there was no mTOR in the nucleus, the anti-HA
antibody was unable to penetrate the nucleus, or the mTOR was not yet transported to
the nucleus. Experiments to follow the movement of mTOR throughout the life cycle
of the cell would provide additional evidence to support the theory that mTOR is
shuttled to and from the nucleus.
The importance of understanding the interactions between these molecules
can not be underestimated. In this thesis we have established that mTOR plays the
roles of both the receptor of cellular signals and as an initiator of cellular pathways.
An understanding of mTOR’s pathways and, those effected by the crosstalk between
the molecules, is vital to the development of drug treatments to manipulate those
pathways.
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VII. SIGNIFICANCE OF THIS STUDY
mTOR is thought to be a master regulator of the cell. Understanding how this
protein kinase is regulated in healthy cells and how it becomes dysregulated in
diseased cells is important to our understanding of many different diseases. This
study produced four HA-tagged mTOR expression plasmids that were effectively
transfected in mammalian cells. These constructs provide the lab with the molecular
tools to study the crosstalk between mTOR and various other molecules.

The

plasmids are available in purified form for the lab and glycerol DH5α stocks exist so
the plasmid can be easily replenished. Each of these plasmids went through extensive
testing including restriction enzyme digestions and sequencing by a third party.
Western Blotting showed that the HA-mTOR plasmid DNA could be
overexpressed in mammalian cells, and detected with both anti-mTOR and anti-HA
antibodies. Kinase assays showed the transfected mTOR was active, and the kinase
dead mutant showed an expectedly decreased phosphorylation ability.

Cells

transfected with these plasmids also showed an increase in mTOR gene expression as
detected by Real-Time PCR.

The HA-mTOR protein was visualized by

immunoflourescence microscopy, which confirmed its perinuclear location.
The results of this study complete the next step in the investigation between
the crosstalk of these signaling molecules.

Gene expression studies should be

continued to further verify the effect of mTOR overexpression on PLD1, PLD2 and
S6K.
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